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CHAPTER I 
 
 
FLUORESCENT IMAGING APPLICATIONS  
OF QUANTUM DOT PROBES [1] 
 
 
Introduction 
 
Highly fluorescent semiconductor nanocrystals, or quantum dots (QDs), were initially 
incorporated into biological imaging applications concurrently by two groups in 1998 [2, 
3].  Since that time, an ever increasing amount of research has been devoted to expanding 
their use in various biological applications.  All of this research’s promise is based upon 
the unique photophysical properties inherent to QDs, which provide numerous 
advantages over conventional organic dyes in several fluorescent imaging applications.  
Specifically, QDs have been engineered to have a narrow, size-tunable fluorescent 
emission which is extremely bright and photostable.  These emission properties are 
characteristically different from organic fluorophores, which generally have broad, log-
normal fluorescent spectra subject to rapid photobleaching.  Consequently, QDs have 
been utilized as improved probes for multiplexed, dynamic imaging applications, both in 
vitro and in vivo, owing to their narrow, photostable fluorescence.  Additionally, their 
improved brightness even facilitates receptor trafficking experiments with enhanced 
sensitivities at the single molecule level.  Despite the promise of these, and a myriad of 
other applications, the primary challenge with any QD-based fluorescence assay involves 
incorporating a suitable QD surface chemistry which will specifically interact with a 
biological target of interest, without interfering with the nanocrystal’s optical properties.   
The unique, size-tunable optical properties of QDs result from the quantum 
confinement of the electron-hole pair, or exciton, formed after the absorption of a photon 
1 
by a semiconductor material.  Confinement of this exciton leads to the emergence of 
discrete electronic states in the nanocrystal and size dependent electronic and optical 
properties.  Several excellent review articles are available which discuss, in greater detail, 
this quantum confinement effect as it relates to biological imaging applications [4-8].  Of 
particular importance is the idea that QDs can be specifically engineered to be highly 
fluorescent by encapsulating one nanocrystalline semiconductor core within a differing, 
wider band gap, semiconductor shell.  This “core/shell” architecture, illustrated 
schematically in Figure 1-1A, is routinely used to generate QDs with exceptionally high 
quantum yields, capable of exceeding 85%.  Structural characterization by means of high 
resolution atomic number contrast scanning transmission electron microscopy (Z-STEM) 
has been used to illustrate the importance of a uniform, defect free shell coverage in the 
synthesis of high quantum yield materials (Figure 1-1B) [9].  This shell acts to passivate 
reactive surface states present on the core, eliminating several non-radiative relaxation 
processes, ultimately allowing for an improved quantum yield.  Additionally, the size 
dependent optical properties permit the fluorescent emission to be tuned across the visible 
spectrum and into the near infrared (NIR) by varying the QD size or composition.  A 
representative series of fluorescent emission spectra, displayed in Figure 1-1C, clearly 
demonstrate this optical tunability and narrow fluorescent lineshape.  Overall, this bright, 
stable, narrow, tunable fluorescence has the promise to expand biological imaging 
applications well beyond current capabilities. 
2 
 Figure 1-1. Properties of biologically compatible semiconductor quantum dots.  (A) Cartoon schematic 
illustrating core/shell architecture and ampiphilic polymer coating rendering the QD water soluble.  (B) 
High resolution atomic number contrast scanning transmission electron (Z-STEM) micrograph of 
individual CdSe cores [9].  At this resolution it is possible to simultaneously identify both atomic 
composition and structural information.  (C) Fluorescent emission spectra for a series of core/shell 
nanocrystals.  Narrow, gaussian emissions can be tuned across the entire visible spectrum by varying either 
particle size and/or composition.  CdSe nanocrystals are of particular interest for fluorescent imaging 
applications since their fluorescent emission can be tuned across the entire visible spectrum.  Incorporation 
of CdTe materials allow for the fluorescence to be extended into the near-IR region which is of great 
interest for in vivo imaging applications. 
 
The development of synthetic strategies for surface modifications which enable water 
solubility, selective targeting, and minimal nonspecific interactions have proven to be a 
significant challenge facing the application of QDs to biological systems.  This chapter 
will highlight developments in surface modification which have allowed for the specific 
targeting of cellular targets, followed by a thorough discussion of recent, noteworthy QD 
3 
fluorescent imaging applications.  The remainder of this chapter will then outline a small 
molecule targeting strategy for the development of fluorescent QD-conjugates as 
improved probes for neurotransmitter transporter proteins. 
 
 
Surface Modification and Biomolecule Attachment 
 
Given the inorganic, hydrophobic nature of these semiconductor nanocrystals, a 
suitable surface modification which primarily renders the QDs water soluble, and further 
limits nonspecific cellular interactions, is of critical importance for the development of 
biologically compatible fluorophores.  This section is initially focused on a discussion of 
methodologies which have been employed to disperse QDs in aqueous solution.  Surface 
modifications which have been designed to limit nonspecific interactions are 
subsequently described, including covalent attachment mechanisms suitable for 
biomolecule functionalization.  Finally, several applications that employ the high affinity 
streptavidin-biotin interaction to facilitate the specific cellular targeting of these QD 
conjugates are discussed.   
 
Water Solubilization 
 
Due to their size dependant optical properties, a monodisperse distribution of QDs is 
absolutely essential to obtain the narrow fluorescent emission spectra desired for 
biological applications.  The traditional synthetic methodology for maintaining this very 
narrow size distribution involves the pyrolysis of organometallic precursors at high 
temperatures in a coordinating surfactant solvent such as trioctylphospine oxide (TOPO) 
[10, 11].  This synthesis yields hydrophobic core/shell nanocrystals which are only 
soluble in non-polar organic solvents due to the alkyl nature of the TOPO coordinating 
4 
surfactant.  The development of biocompatible conjugates is primarily dependent upon 
the ability to render these as-synthesized hydrophobic nanocrystals water-soluble.  Initial 
strategies at water solubilization all employed a ligand exchange strategy to displace the 
hydrophobic surfactant from the QD surface altogether.  This ligand exchange 
methodology utilizes a reactive free thiol to displace the TOPO coordinating surfactant 
ligands replacing them, instead, with hydrophilic moieties.  Silinazed QDs [2, 12], 
mercaptoacetic acid (MAA) [3, 13] mercaptoundecanoic acid (MUA) [14] QDs, and 
dihydrolipoic acid (DHLA) modified QDs [15-17] all employ this ligand exchange 
methodology to stabilize the nanocrystal in aqueous media.  Despite several initial 
advances with these types of nanocrystal, chemical modification directly at the QD 
surface has been shown to be more likely to have an effect on their desired optical 
properties. The long term stability of these nanocrystals in aqueous solutions has also 
been called into question. 
In order to overcome these shortcomings, alternate strategies to disperse the QDs in 
aqueous solutions have been developed which utilize bifunctional 
hydrophobic/hydrophilic compounds to self assemble onto the hydrophobic QD surface.  
In this architecture the hydrophobic organic capping ligands are retained, but they are 
encapsulated in a lipid or bifunctional polymeric material with sufficient hydrophilicity to 
disperse the QDs in aqueous solutions.  An initial example of this approach used 
phospholipids to encapsulate QDs in the hydrophobic core of a micelle [18].  In this 
experiment, a mixture of n-polyethylene glycol phosphatidylethanolamine (PEG-PE) and 
phosphatidylcholine (PC), micelle-forming polymer-grafted lipids, were allowed to 
assemble onto the surface of the QD forming a water soluble micelle, effectively trapping 
5 
a QD in the hydrophobic core.  This resulted in a suspension of nanocrystals with 
improved colloidal stability and minimal nonspecific cellular interactions.  A similar 
methodology utilizes ampiphilic polymers to encapsulate the hydrophobic QD in a 
hydrophilic polymeric shell [19-21].  As illustrated in Figure 1-1A, the alternating nature 
of the ampiphilic polymer allows the hydrophobic alkyl chains to intercalate with the 
TOPO ligands present on the QD surface, while the hydrophilic carboxylic acid 
functionality renders the nanocrystal water soluble.  These carboxylic acids also permit 
further functionalization as a means to introduce biological specificity.  Additionally, 
these QDs have been shown to display excellent stability in aqueous solutions and, since 
there is no chemical reaction directly at the QD surface, the inherent photophysical 
properties are retained.  This type of hydrophobic/hydrophilic assembly has emerged as 
the preferred methodology for biological imaging applications, as is evident by the 
extensive commercial development of these probes.  Notably, Evident Technologies® has 
adopted the phospholipids micelle approach for their water soluble product line; while 
Invitrogen® (which acquired Quantum Dot Corp.) utilizes ampiphilic poly(acrylic) acid 
(AMP) coated QD as the basis of all their commercially available QD-congujates.  
Although detractors may claim improved specificity and decreased hydrodynamic 
diameter of alternate approaches, the improved colloid stability and optical properties 
outweigh these disadvantages for most applications.       
 
Reduction of Nonspecific Cellular Interactions 
Having addressed the initial challenge of rendering QDs water soluble, 
methodologies for eliminating nonspecific cellular interactions to generate optimized 
6 
fluorescence detection will be discussed.  Given the widespread utilization of the AMP-
QD platform, the remaining discussion will focus on surface modifications of this 
particular platform for optimized incorporation in biological applications.  It has been 
reported that the carboxylic acid functionality on the surface of AMP-QDs lead to 
nonspecific interactions with oligonucleotides [22], and passivation of this surface with 
PEG derivatives reduces these nonspecific interactions in mouse animal models [23].  
Consequently, nonspecific binding (NSB) of AMP-QDs to a cell’s surface is presumably 
the result of a combination of both hydrophobic/hydrophilic and electrostatic interactions 
of the reactive carboxylic acid surface with the cell’s plasma membrane and surface 
proteins.  This interaction has also been demonstrated to be highly dependent upon the 
different cell lines employed in various studies [24].  As illustrated in Figure 1-2, 
differing cell types clearly yield a differential amount of NSB ranging from extremely 
high backgrounds in HEK cells, moderate labeling in HEp-2 and CHO cell lines, to 
minimal interactions with LLC cells.  In all cases, however, modification of the AMP-QD 
surface with PEG reduces the amount of NSB present, regardless of cell line.  PEG 
modification, consequently, allows a generalized approach for the reduction of the NSB 
of QDs to both live and fixed cells.   
Standard immunohistochemical blocking strategies, such as bovine serum albumin or 
fetal bovine serum blocking solutions, can also be used in conjunction with these surface 
modifications to further reduce NSB.  Care must be taken, however, to optimize blocking 
conditions for the particular system of interest as demonstrated by Pathak et al. [25].  
Additionally, Hanaki et al. have demonstrated the capability of QD-albumin complexes 
to associate in the endosomes of living cells  [14].   As a consequence, one must carefully 
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ensure that albumin, present in standard blocking solutions, is not complexing to the QDs 
and interfering with the observed biological interaction.  This seemingly subtle 
association introduces the possibility of numerous false positives and other interferences 
associated with QD-based live cell imaging applications.  Complete passivation of the 
QD surface with PEG ensures minimal albumin-QD association and can be verified by 
standard chromatographic techniques, as demonstrated by Zimmer et al. for extremely 
small InAs/ZnSe core/shell QDs [26]. 
 
 
Figure 1-2. Comparison of the non-specific interactions of 30 nM AMP-QDs (top images) to 30 nM PEG-
QD conjugates (bottom images).  Non-specific binding of AMP-QDs varies in intensity for different cell 
lines, as illustrated for (from left to right) HEp-2, LLC, HEK, and CHO cells.  In all cases, however, PEG 
surface modifications reduce these non-specific interactions, allowing for improved specificity and 
sensitivity of detection.  Adapted from [24]. 
 
Covalent Conjugation Methodologies 
Taking into account the modifications required to eliminate, or at least reduce, 
nonspecific cellular interactions, this section will detail attachment strategies available 
for further modifications to the QD surface in order to introduce biological specificity of 
QD probes to a given cellular target.  Numerous attachment strategies are available given 
the reactive carboxylic acid functionality of the AMP-QD surface.  Covalent attachment 
8 
by means of a 1-ethyl-3-(3-dimethylaminopropyl) carboiimide (EDC) coupling has been 
reported extensively.  This EDC coupling strategy is widely employed in general peptide 
synthetic chemistry as it covalently attaches a carboxylic acid to a terminal amine [27].  
As terminal amines are prevalent in antibodies and peptides, and can be introduced into 
small molecule derivatives, this methodology permits covalent attachment of a wide 
variety of biomolecules directly to the QD surface.  In the rare case where no terminal 
amine is available, or in order to avoid crosslinking compounds with multiple terminal 
amines present, an alternate covalent attachment of a free thiol can be carried out via a 
malemide coupling.  This attachment methodology involves first coupling a bifunctional 
linker arm with both amine and sulfhydryl reactivity (i.e.  SMCC, Sigma Aldrich Cat. # 
M5525) via EDC coupling to introduce a malemide to the surface of amine terminated 
QDs.  This malemide can then be allowed to form a covalent bond with a free thiol, often 
providing a more selective attachment of biomolecules.  These two covalent attachment 
mechanisms, EDC and malemide, have been the predominant methodologies employed to 
modify the AMP-QD surface to facilitate a specific interaction with a cellular target. 
 
Streptavidin-Biotin Assembly 
One alternate attachment methodology incorporates the extremely high affinity 
streptavidin-biotin interaction to specifically target cellular processes.  This approach was 
initially proposed in the first reported application of QDs for biological imaging [2], and 
has since found wide scale use due to commercially available products from both 
Invitrogen® and Evident Technologies.  While this interaction is not intrinsically covalent 
in nature, it is one of the tightest non-covalent interactions known, with a sub-picomolar 
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dissociation constant and off rates on the order of days [28].  Additionally, streptavidin 
conjugates yield very little endogenous labeling and are stable for several months in 
solution.  Several noteworthy applications have employed streptavidin-conjugated QDs 
for attachment to a specific biotinylated biomolecule.  Lidke et al. conjugated a 
biotinylated epidermal growth factor (EGF) to streptavidin-QDs and were able to 
dynamically observe retrograde transport of individual conjugates and monitor their 
subsequent endosomal trafficking [29].  The QDs’ inherent photostability permits these 
dynamic cellular processes to be imaged on time scales previously unattainable with 
organic dyes.  Additionally, this experiment provides verification that the seemingly 
bulky size of the QD-streptavidin conjugate does not sterically interfere with the binding 
and function of the EGF ligand.  Streptavidin conjugated QDs have also been employed, 
following attachment of biotinylated kinesins, to elucidate the intracellular dynamics of 
these single molecular motors [30].  Similarly, biotinylated Annexin V conjugated to 
streptavidin QDs has been shown to specifically target apoptotic cells via recognition of 
phosphatidylserine, an inner-leaflet phospholipid present in the outer-leaflet of the cell 
membrane during programmed cell death [31].  While these three examples all utilize 
biotinylated versions of receptor-specific proteins, there is an extensive literature 
precedent showing that biotinylation of any biomolecule (i.e. antibody, peptide, DNA, or 
small molecule) is a suitable mechanism for QD conjugation. 
Recently, Howarth et al. have proposed an alternate and extremely versatile method 
for the attachment of QDs to a variety of surface proteins in vitro [32].  This approach, as 
illustrated in Figure 1-3A, uses the Escherichia coli enzyme biotin ligase (BirA) to 
covalently attach biotin to a fifteen amino acid sequence called the acceptor peptide (AP).  
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Specificity is introduced by genetically encoding the AP sequence at the C or N terminus 
of the target protein.  Since specificity is not dependant upon antibody-antigen or ligand-
receptor type interactions, which have varying degrees of instability, the resulting 
labeling is extremely robust and essentially covalent in nature, given the extremely high 
affinity of streptavidin for biotin.  Additionally, the overall size of the QD probe is 
reduced since no further biomolecule attachment is necessary to facilitate a specific 
interaction.  In this initial paper, the authors genetically introduce the acceptor peptide 
sequence into both the platelet-derived growth factor receptor and glutamate receptor 
subunit 2 (GluR2, Figure 1-3B) and observe QD labeling for both, demonstrating the 
versatility of this approach.  Furthermore, a point mutation in the AP sequence, or 
experiments performed in the absence of either BirA or biotin, result in no observable 
QD labeling, illustrating exquisite specificity.  Receptor trafficking experiments were 
subsequently performed and seem to indicate decreased accessibility of QD-labeled 
GluR2 receptors to neural synapses compared to organic dye labeled receptors, 
presumably as a result of the QD’s relatively bulkier size (Figure 1-3B).  Similar receptor 
trafficking experiments have since been performed by an alternate group which utilize 
this enzymatic biotinylation as a means of targeting streptavidin QDs to Kv2.1 potassium 
channels [33].  It is apparent that enzymatic modification of cell surface proteins can now 
be considered a specific, sensitive and versatile approach for in vitro QD labeling 
applications. 
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 Figure 1-3. Enzymatic modification of target protein and subsequent QD labeling proposed by Howarth et 
al.  (A) An acceptor peptide (AP) sequence, GLNDIFEAQKIEWHE, is first genetically encoded at the C or 
N terminus of the protein of interest.   Biotin ligase (BirA) then enzymatically attaches biotin, in the 
presence of ATP, to this AP.  Finally, streptavidin-conjugated QDs are allowed to bind the biotin, resulting 
in a specific and extremely stable interaction.  (B) Detection of QD labeling in hippocampal neurons 
expressing an AP-tagged glutamate receptor (AP-GluR2) and the synaptic marker PSD-95-YFP.  Exposure 
to BirA for 10 min at 37 °C, and subsequent staining with streptavidin-QD605, results in the specific QD 
labeling of AP-GluR2 (top).  A zoomed in view (bottom) illustrates that some synaptic AP-GluR2 
molecules, indicated by PSD-95-YFP, are not accessible to the streptavidin QDs, presumably due to the 
QD size.  Reproduced with permission from [32]. 
 
Conjugates to Introduce Biological Specificity 
    
Directing QDs to specifically interact with a particular cellular target has traditionally 
been accomplished by biomolecule conjugation.  Broadly categorized, this biological 
specificity has been introduced by attachment of either antibody [16, 19, 34-42], peptide 
[13, 42-56], DNA [18, 22, 57-60], or small molecule [61, 62] biomolecules.  
Consequently, these resulting QD-conjugates function as a nano-scaffold, incorporating 
biological functionality to facilitate a specific interaction while retaining the improved 
spectroscopic properties of the QD.  In this section, advantages and disadvantages of 
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differing approaches which have been used to introduce biological specificity will be 
discussed. 
Antibodies have been used extensively in QD imaging applications due to both the 
specificity introduced by the antibody-antigen interaction, as well as the plethora of 
antigen targets obtainable by established antibody production techniques.  Additionally, 
standard immunohistochemical labeling protocols, initially developed for conventional 
fluorophores, are easily applied to QD-based systems.  As a general method, a primary 
antibody is initially used to target the specific cellular target of interest, and a secondary 
antibody attached to a QD, either covalently or through a streptavidin-biotin bridge, is 
then used to detect the primary antibody.  While this two step scaffolding approach may 
seem somewhat redundant, it is often employed to conserve supplies of the expensive 
primary antibody, and also allow one type of QD conjugate to label a wide variety of 
cellular targets.  Alternately, primary antibodies can be covalently attached directly to the 
QD via standard, commercially available coupling techniques circumventing the 
necessity of this two-step approach.   Regardless of the protocol employed, QD 
immunofluorescent labeling has been demonstrated for targets ranging from membrane 
bound cancer markers [19, 21, 37], to glycoproteins [16], neurotransmitter receptors [34], 
viral fusion proteins [35], and immunological cytokine receptors [40].  Despite the 
diversity of targets available to this approach there are, however, associated 
disadvantages with these antibody conjugates.   Of primary concern, antibodies are 
generally expensive; often times costing several hundred dollars for a few precious 
micrograms, assuming of course that a commercially available antibody even exists.  
Secondly, while the antibody-antigen interaction is generally strong, it is variable from 
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antibody to antibody which introduces added experimental complexity.  Finally, the 
relatively large size of the antibody (~150 kDa) adds increased steric bulk to the already 
sizeable QD probe.  Despite these noteworthy disadvantages, antibody conjugates 
continue to provide a versatile targeting approach for QD-based fluorescent assays.   
Peptide conjugates have also been employed as a means of introducing biological 
specificity for QD targeting applications.  Peptides, the building blocks of proteins, are 
biologically relevant amino acid sequences that interact with proteins through sequence-
specific peptide-protein interactions.  Once again, as in the case of antibody recognition, 
the strength of these peptide-protein interactions are highly variable, but peptides have 
the added advantage of being considerably smaller in size and have significantly less 
expense associated with synthesis.  Signaling peptides involved in post translational 
transport of proteins, such as the nuclear localization signal (NLS) peptide, have been 
attached to QDs and demonstrate effective delivery to assigned cellular organelle [44, 
52].  Cationic cell-penetrating peptides, such as TAT, Pep-1 and poly-arginine sequences, 
have been employed to facilitate intracellular delivery of QD probes [51, 53, 54], while 
arginine-glycine-aspartic acid (RGD) peptides have proven to efficiently direct QDs to 
integrin αvβ3, a cell surface receptor overexpressed in several tumor vasculatures, both in 
vitro and in vivo [42, 45, 55].  Additionally, angiotensin, a circulating peptide involved in 
signaling cascades for the cardiovascular, renal and central nervous systems, has been 
used with QDs to interrogate angiotensin receptor expression in vitro [48, 56].  A 
significant drawback with peptide mediated QD targeting approaches is that they cannot 
be universally applied to any given cellular target, as these techniques are only effective 
in systems where a known peptide functions as a natural substrate.  As a result, peptide 
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conjugation lacks the diversity of an antibody-based approach, but still continues to 
facilitate numerous imaging applications. 
Biological recognition can also be incorporated in the QD nanoarchitecture through 
the use of biologically active small molecule conjugates.  These small molecule 
nanoconjugates rely on ligand-receptor interactions to provide specificity.  While the 
nature of these interactions is variable in strength, they can be systematically optimized 
through improved ligand design.  Additionally, this small molecule targeting approach 
can design conjugates that elicit either an agonistic or antagonistic response, which is to 
say they can either cause or inhibit a physiological response subsequent to binding, 
providing an additional degree of experimental control for imaging experiments.  The 
cost associated with synthesis is reduced compared to either antibody or peptide 
conjugates, and the size of the biomolecule is obviously not as significant a concern as in 
the antibody conjugate.  Also, an extremely wide variety of cellular targets are available 
either through rational ligand design based on a receptor’s known substrate or derivatives 
of drug candidates from the known pharmocopia.  The feasibility of this approach was 
initially demonstrated with the specific labeling of serotonin transporter (SERT) proteins 
using serotonin derivatized QDs [61], and has since been applied to gamma-aminobutyric 
acid (GABA) neurotransmitter receptors with muscimol-conjugated QDs [62].  As with 
previous methodologies, there are associated limitations of this approach including a 
time-consuming, iterative ligand optimization process, which will be described in greater 
detail in a subsequent section of this chapter.  Additionally, ligand presentation (i.e. 
surface coverage of the nanocrystal, linker arm composition, linker length, etc.) has to be 
optimized for each small molecule to insure a suitably robust interaction with a cellular 
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target.  Continued development, however, should alleviate some of the technical 
difficulties associated with small molecule design and presentation, ultimately allowing 
for an increasingly versatile QD targeting methodology.   
Alternate approaches also exist for incorporation of QDs into biologically relevant 
assays, although they are currently limited in number compared to these conventional 
biomolecule attachment methodologies.  Utilizing specific DNA interactions, QDs have 
been shown to be effective fluorescence in situ hybridization (FISH) probes following 
surface derivatization with oligionucleotides [57-60].  Additionally, non-targeted QDs 
can also be incorporated into biological assays without any additional biomolecule 
attachment.  An assay to measure metastatic potential by imaging phagokinetic tracks 
utilizes QDs without any specific biological recognition functionality [63], and passive 
endocytosis of non-targeted QDs proved sufficient to demonstrate the improved 
sensitivities of these probes via time-gated fluorescence imaging [64].  Recent 
applications have even demonstrated QD self-assembled encapsulation in viral capsids 
yielding a particle similar in many respects to a native virus [65].  Undoubtedly, alternate 
and novel surface modifications, which may ultimately incorporate improved biological 
recognition elements, will continue to emerge given the continued expansion of research 
in this field.  In the meantime, however, sufficient targeting options are currently 
available which have allowed for numerous QD-based fluorescent imaging applications.   
 
Previously Reported Quantum Dot Imaging Applications 
   
Having addressed the current scaffolding techniques for incorporation of QDs into 
biological assays, several reported applications utilizing these biologically compatible 
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QDs which allow for improved fluorescent imaging experiments will now be highlighted.  
While the superior spectral characteristics of QD fluorophores continues to allow for 
further improvement beyond existing fluorescence imaging limitations, this section will 
hopefully provide a snapshot of what is currently considered to be state-of-the-art in QD 
imaging methodology. 
 
Multicolor Fluorescent Imaging 
The narrow fluorescent emission spectra of QDs have always been associated with an 
added promise of increased multiplexing capabilities.  While multicolor detection is 
certainly not out of the realm of possibility for conventional organic fluorophores, the 
presence of added fluorophores always results in increasing spectral overlap of their 
comparatively broad fluorescent emissions.  As such, multiplexed experiments with more 
than three fluorophores, while certainly possible, has generally required specialized 
spectral deconvolution algorithms and added experimental complexity.  Multiplexed QD 
detection, on the other hand, can be routinely performed with at least six spectrally 
isolated fluorescent probes, all commercially available, without the necessity of added 
image processing.  Certainly, the application of QD probes to both western blot analyses 
[66] and FISH techniques [57] has reportedly improved the detection capabilities of these 
methodologies.  Recently, an exquisite demonstration of the multicolor fluorescent 
imaging capabilities of commercially available QD fluorophores has been reported by 
Fountaine et al. [67].  This report has utilized a sequential immunohistochemical QD 
labeling technique to simultaneously detect five cell line-specific antigens in tonsil and 
lymphoid tissue.  As such, antibodies specific to CD20 and IgD, both B cell markers, 
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CD3, a T cell indicator, CD68, a macrophage marker, and MIB-1, indicating the 
proliferative areas of a germinal center, allowed for the specific and simultaneous 
detection of differentially expressed surface, cytoplasmic and nuclear antigens.  
Obviously, the continued application of QDs to these types of multiplexed experiments 
will facilitate clinically relevant investigations of multidimensional cellular interactions.   
Perhaps the most striking demonstration to date of the superior multiplexing 
capabilities of QD fluorophores is the recent application of QDs to polychromatic flow 
cytometry analyses.  Recently, Chattopadhyay et al. have reported the resolution of 
seventeen fluorescent emissions through the incorporation of QD fluorophores [68].  
This seventeen color analysis, consisting of eight colors of QDs in conjugation with nine 
other conventional fluorophores, was used in immunophenotyping experiments on 
various T cell populations.  The ability to independently quantify at least 17 fluorophores 
on a cell-by-cell basis vastly extends the capability of flow cytometry technology and 
allows for the design of considerably more complex experiments.  The promise of truly 
multiplexed experimental design through the incorporation of QD fluorophores is 
increasingly being realized for a variety of applications.  Continued improvement, 
through improved synthetic methodologies resulting in even narrower fluorescent 
emissions, may well extend these capabilities even further in the years to come. 
 
Dynamic Receptor Trafficking 
QDs’ inherent photostability and brightness have recently allowed an increasing 
number of applications which monitor the trafficking dynamics of cellular receptors at 
the single molecule level.  Dahan et al. initially demonstrated single molecule tracking 
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experiments investigating the cellular trafficking of individual glycine receptors (GlyR) 
in the neuronal membrane [34].  Individual QDs, presumably interacting with individual 
receptors, were identified by the fluorescent intermittency, or blinking, characteristic of 
single nanocrystals.  This intermittency, a result of a combination of both radiative and 
nonradiative relaxation pathways present in the nanocrystal, is a useful signature for 
identification of individual QDs and has been reviewed elsewhere [8, 69, 70].  In this 
study, the QD’s added photostability routinely permitted visualization of individual 
GlyRs for time frames exceeding 20 minutes, compared to imaging durations of only five 
seconds for conventional Cy3 coupled antibodies.  Additionally, the signal-to-noise ratio 
for the QDs was almost a full order of magnitude larger than those obtained with standard 
fluorophores as a result of improved brightness.  Antibody-QD conjugates specifically 
targeted to GlyRs (Figure 1-4), were found to be located at the synapse (synaptic), 
alongside the synapse (perisynaptic), or away from the synapse along the dendrite 
(extrasynaptic).  Notably, the diffusion coefficients of these receptors were found to be 
dependant upon this membrane localization, illustrated in Figure 1-4C, generally showing 
decreased diffusion for synaptically associated receptors and increased rates of diffusion 
for extrasynaptic receptors.  This report serves as an excellent illustration that the optical 
properties of QDs enable dynamic monitoring of individual molecules within a cellular 
environment.  
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 Figure 1-4. Glycine receptor trafficking with single-QD detection.  (A) Localization of QD-GlyRs (red) in 
neuronal cultures identified by microtubule-associated protein-2 (green).  Arrows indicate clusters of QD-
GlyRs on dendrites.  (B) Relation of QD-GlyRs with inhibitory synaptic boutons labeled for vesicular 
inhibitory amino acid transporter (green).  (C) Localization was observed to be either stable at synapses (s), 
perisnyaptic (p), or extrasynaptic (e).  The observed cumulative probability of diffusion coefficients 
differed as a function of their membrane location.  From [Dahan, M.; Levi, S.; Luccardini, C.; Rostaing, P.; 
Riveau, B.; Triller, A. Science, 2003, 302, 442-445].  Reprinted with permission from AAAS. 
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Since this first reported application, an increasing amount of research has been 
devoted to QD-based molecular tracking experiments.  Dynamic imaging of QD probes 
has allowed for the elucidation of a novel retrograde transport mechanism in filopodia 
[29], and has been applied to glutamate receptors [32], as well as intracellular molecular 
kinesin motors [30, 50].  More recently, dynamic QD imaging has been employed to 
monitor tyrosine kinase A (TrkA) receptor dynamics in neuronal cell cultures.  Vu et al. 
initially demonstrated the ability of the βNGF peptide, the beta subunit of nerve growth 
factor, to specifically direct QDs to surface bound NGF-TrkA receptors in PC12 cell 
cultures.  Additionally, they report that βNGF-QD conjugates are effective at activating 
these neuronal receptors, initiating downstream signaling and neurite growth, albeit with 
a diminished activity compared to free βNGF [46].  A subsequent study utilized these 
βNGF-QD conjugates as well as antibody conjugates to visualize the endocytosis, 
redistribution, and shuttling of NGF-TrkA receptors to PC12 neuronal processes and 
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growth cone tips [47].  Transport and concentration of βNGF-QD-TrkAs at the growth 
cone tips was observed, consistent with normal trafficking of fluorescent protein-tagged 
TrkA and myc-tagged NGF.  This is further illustration that QDs do not act to hinder 
receptor activity or diffusion, and can serve as effective probes to visualize receptor 
trafficking.  
 
In Vivo Imaging 
Another area which has recently seen a dramatic increase in the amount of research 
devoted to the incorporation of QDs is in vivo imaging applications.  Once again, the 
unique optical properties of QDs offer several advantages over existing fluorophores.  Of 
particular interest for in vivo applications is the QDs’ tunable fluorescent emission, which 
can span into the near-infrared (NIR) regime.  This region, known as the ‘water-window,’ 
provides reduced autofluorescent background from the tissue and an improved tissue 
penetration.  Additionally, initial in vivo studies have demonstrated enormous two-photon 
action cross sections for QD probes, a direct measure for brightness with two-photon 
imaging, allowing for further improvements in tissue imaging depths [71].  Other studies 
have also shown that PEG surface modifications reduce clearance by the 
reticuloendothelial system enabling longer circulation times in vivo [13, 23].  To date, 
QD-based in vivo imaging applications have been predominantly applied towards cancer 
research with a great deal of work directed towards tumor targeting.  In one application, 
non-targeted QDs with a polydentate phosphine coating have been shown to accumulate 
in the sentinel lymph node facilitating fluorescent contrast for major cancer surgery [72].  
Alternate approaches, where cells were initially labeled with QDs ex vivo and then 
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tracked following in vivo administration, have been employed to monitor metastatic 
tumor cell extravasation [73] and differentiate tumor vessels from perivascular cells and 
matrix [43].  Targeted, intravenous delivery of QDs to tumor tissues has been 
demonstrated with peptide-QD conjugates designed to preferentially recognize elements 
of the tumor vasculature [13], as well as antibody recognition for directed tumor targeting 
to prostate-specific membrane antigen [21].  In a recent in vivo application, RGD peptide 
conjugated QDs have been utilized for the directed targeting and imaging of tumor 
vasculature [45].  Furthermore, experiments have been performed to analyze the 
trafficking of single QD conjugates within the tumors of living mice by means of a 
skinfold chamber and confocal microscope [74].  Development of improved QD probes 
for NIR in vivo imaging applications continues to have great potential for cancer 
diagnosis and treatment, as well fluorescent imaging-guided surgery and therapy. 
 
Further Biological Applications 
QDs are also uniquely suited to facilitate a number of multimodal imaging 
applications.  While fluorophores are routinely employed in conventional light 
microscopy techniques, these applications are fundamentally limited with regards to 
spatial resolution as a result of the diffraction limit described by Rayleigh’s criterion.  
QDs, however, have the added benefit of being both fluorescent and electron dense, 
allowing for the incorporation of the additional resolution of the electron microscope for 
certain biological imaging applications.  Recently, QDs were employed in a correlated 
microscopy application, which allows the mapping of proteins with fluorescent 
microscopy and the higher resolution localization at the ultrastructural level with electron 
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microscopy [36].  This technique, however, is critically dependant upon sample 
preparation and utilizes a novel sample holder which permits imaging on both 
microscopes.  In one protocol described in this study, two colors of antibody-QD 
conjugates were used to stain connexin43 (Cx43), a gap junction indicator, and 
microtubles in fixed RFL6 fibroblasts which were subsequently embedded on an epoxy 
resin and mounted on an acrylic support.  Initial low magnification fluorescent 
microscopy (20x) of the entire sample area allowed for navigation through the specimen 
at higher magnification to obtain coincidental fluorescent (63x oil immersion) and 
electron micrographs of the same field of view.  The overlaid fluorescent and electron 
micrographs presented in this report are illustrative of the unprecedented spatial 
resolution obtainable in cellular colocalization imaging applications through the use of 
QDs with correlated light and electron microscopy. 
An alternate bimodal imaging application has been demonstrated through the 
incorporation of paramagnetic gadolinium into the QD architecture to provide contrast 
for magnetic resonance imaging (MRI) [75-77].  Gadolinium has been effectively 
introduced though lipid coatings on the QD surface, allowing the QD to retain its 
fluorescent properties, resulting in a versatile probe for noninvasive imaging with both 
MRI and fluorescent techniques.  Additionally, QDs have shown promise for 
photodynamic therapy applications [78], as well as targeted drug delivery [79].  The 
multivalent nature of the QD surface can, conceivably, be modified to incorporate both 
targeting and drug compounds, ultimately providing an improved platform for a targeted 
delivery of therapeutic payloads.  Sophisticated attachment strategies have also been 
suggested to include an enzymatically cleavable region which provides an additional 
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level of control for selective drug delivery [80].  All of these applications, in order to 
meet their therapeutic potential, require that the QDs themselves have no deleterious 
effect on cell physiology.  Differing reports throughout the scientific literature have tried 
to asses the level of cellular toxicity associated with QD exposure.  An excellent review 
has illustrated that QD cytotoxicity is critically dependent upon numerous 
physiochemical and environmental factors [81].  Regardless, continued research will 
undoubtedly provide a more definitive determination of the cytotoxic effects of QDs, 
ultimately allowing for a comprehensive understanding regarding the nature of these 
cellular interactions. 
 
Small Molecule Synthetic Strategies 
 
 The remaining discussion will detail the design and synthesis of high-affinity ligands 
for the dopamine transporter (DAT) as an illustration of a small molecule-QD targeting 
approach currently in development by the Rosenthal research group.  DAT, an 80 kDa 
integral membrane protein [82], acts to remove excess dopamine from the synaptic cleft 
via a sodium chloride coupled transport mechanism.  It has a primary amino acid 
sequence of 620 residues consisting of twelve transmembrane hydrophobic stretches with 
both the C and N termini located intracellularly [83, 84].  DAT is located on the 
presynaptic membranes of mesotelencephalic dopaminergic neurons which are located in 
the substantia nigra and ventral tegmentum in the midbrain and converge in the basal 
ganglia of the forebrain [85].  Changes in both dopamine receptor distribution and the 
dopamine transporter system have been shown to be important factors in a number of 
different disease states including Parkinson’s disease, Huntington’s chorea and 
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schizophrenia [85].  Additionally, the dopamine transporter system has been shown to be 
responsible for the locomotor and reinforcing effects of cocaine [86].  The development 
of high-affinity ligands specific to DAT and their subsequent attachment to QDs will 
result in highly fluorescent conjugates, enabling the imaging of localization and 
distribution of DAT in neuronal cell cultures.  Ultimately, the ability to dynamically 
interrogate DAT’s distribution and localization in response to applied stimuli will provide 
a better understanding of these disease states as well as the dopaminergic role in cocaine 
addiction.    
The initial step in the development of these fluorescent QD-conjugates involves the 
identification of a suitable ligand which will interact with DAT selectively.  Many 
different classes of compounds have been demonstrated to bind to DAT, some of which 
include phenyl tropanes, 1,4-dialkyl piperazines, hybrid tropane 1,4-piperazine 
derivatives, phencyclidines and Mazindol derivatives [82, 87-90].  The DAT antagonists 
GBR 12909 and GBR 12935 are 1,4-dialkyl piperazine derivatives, illustrated in Figure 
1-5, have been studied extensively [91-93].  Microdialysis experiments have shown that 
GBR 12909 attenuates the extracellular dopamine levels enhanced by cocaine in rat 
striatum, and there is also evidence that this ligand dissociates from the transporter 
slowly, resulting in a long duration of action [92, 94-100].  Additionally, structure 
activity studies reported for GBR 12935 indicate that derivatives with a substituent on the 
phenyl ring via a propyl piperazine attachment retain their biological activity.  
Furthermore, competitive inhibition assays indicate effective binding of both GBR 12909 
and GBR 12935 to DAT, with IC50 values in the nanomolar range.  The biological 
properties and ease of synthesis of these GBR compounds make them ideal candidates for 
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the development of small molecule-QD conjugates which will aid in the development of 
highly selective and sensitive fluorescence-based assays.  In this section, we report the 
synthesis of analogues of GBR 12909 and 12935 that retain a high affinity for DAT while 
also allowing for covalent attachment to the surface of fluorescent nanocrystals.   
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Figure 1-5. Structure of GBR 12935 and GBR 12309, 1,4-dialkyl piperazine derivatives which are 
extremely potent and selective inhibitors of the dopamine transporter. 
 
Initial drug derivatives were based upon the parent compounds GBR 12935 and GBR 
12909 (shown in Figure 1-5).  Two noteworthy derivatives, previously reported, with 
modifications to the phenyl ring that do not interfere with biological activity are 
illustrated in Figure 1-6.  An azido derivative (I), with a bulky iodo substituent on the 
phenyl ring, has been utilized for photo-affinity labeling studies of DAT [101].  Also, a 
biotinylated derivative (II) has been synthesized [102] and is routinely used in the 
purification of DAT expressing cells following attachment to avidin coated magnetic 
beads (Kaspar Zimmermann, private communication).  Given this structure activity 
information, it was assumed that attachment of a linker arm to the para position of the 
phenyl ring on the propyl chain would not interfere with the ligand’s high affinity for 
DAT.  Selective substitution at this para position can be carried out using an amino 
modified analogue which has been reported in an earlier publication [103].  As indicated 
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in Scheme 1, the synthesis of this parent compound can be carried out utilizing relatively 
inexpensive starting materials (the detailed synthetic strategy is outlined in [103]).  
Linker arms can subsequently be attached selectively to this para-amine modification via 
an acid chloride, resulting in the formation of the appropriate amide bond.  Thus, this 
parent analog ultimately allows for the attachment of a variety of linker arms selectively 
at the para position of the phenyl ring.  Compounds (III), (IV), (V) and (VI), all 
illustrated in Figure 1-7, were synthesized by means of this method in order to examine 
the linker arm’s effect on the ligand’s affinity for DAT. 
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Figure 1-6. Previously reported GBR 12935 derivatives that retain biological activities.  (I) An azido 
derivative, with a bulky iodo substituent on the phenyl ring, applied to photo-affinity labeling of DAT 
[101].  (II) A biotinylated derivative used in the purification of DAT expressing cells [102]. 
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Scheme 1. Synthesis of parent para-amino GBR 12935 derivative. 
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Figure 1-7.  Initial GBR derivatives incorporating a linker arm functionality.  EDC coupling chemistry was 
used to attach either acetic acid functionality (III), polyethylene glycol linker (IV), or and alkyl spacer (V) 
to the parent para-amino GBR 12935 derivative.  In a similar fashion, a GBR 12909 derivative was also 
synthesized with an alkyl linker arm at the para position (VI). 
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Optimization of the composition and length of this linker arm must be performed in 
order to ensure that this chemical modification does not interfere significantly with the 
biological interaction of the ligand.  Determining the biological activity of each 
intermediate can be performed using a competitive uptake assay.  This assay measures 
the ability of either a ligand or a ligand-QD conjugate to inhibit substrate uptake, and is 
quantified radiologically for DAT using tritiated-dopamine as the substrate.  
Experimentally, treating the cells with increasing amounts of ligand in the presence of 
tritiated-dopamine allows for the determination of an IC50 value, the concentration of 
ligand which causes 50% inhibition of the transporter’s activity.  Consequently, these 
IC50 values represent a measure of the biological activity of these conjugates.   A low 
IC50 value implies a stronger interaction with the transporter and a reduced uptake of 
[3H]dopamine; while a larger IC50 value is indicative of a weaker interaction with the 
transporter allowing for increased uptake.   
The biological activities of compounds (III), (IV), (V) and (VI) were measured by 
means of this competitive uptake assay, and the IC50 values are presented in Table 1.  Of 
particular interest is the significant reduction in activity due to polyethylene glycol 
substitution at the para position of the phenyl ring for compound (IV).  Previous structure 
activity studies have indicated that GBR 12935 binds to a hydrophobic cleft or pocket 
within the DAT transporter, which is consistent with this observed loss of activity due to 
addition of the hydrophilic polyethylene glycol functionality.  Additionally, this loss of 
activity is not observed for compounds (V) and (VI), both of which have alkyl 
substitutions at the same para position, presumably due to the hydrophobic nature of this 
linker arm allowing for a stronger interaction with the hydrophobic binding site.  
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Compounds (IV) and (V) were synthesized with a terminal thiol functionality to allow for 
attachment directly to the surface of the QD via a Lewis acid-base interaction, and the 
IC50 values for these QD-conjugates are also presented in Table 1.  While the measured 
IC50 values indicate that these conjugates are indeed biologically active, this type of 
surface modification has several drawbacks including increased non-specific interactions 
with cellular membranes in fluorescent imaging assays.  Additionally, as these ligands 
were not conjugated irreversibly, over the course of several months the ligand had a 
tendency to dissociate from the surface of the QD causing them to aggregate and 
precipitate from solution.  In order to improve the long-term stability of the QD 
conjugates and reduce the associated non-specific interactions, the conjugation 
methodology was modified to utilize alternate quantum dots which have been 
encapsulated in an ampiphilic polymer (ITK-QdotsTM, Invitrogen; formerly AMP-
QdotsTM, Quantum Dot Corporation), supplied as a gift from Quantum Dot Corporation. 
 
Table 1. IC50 values of initial GBR derivatives both as free ligands or QD-conjugates. 
Compound # IC50 (nM) Free Ligand 
IC50 (nM) 
Bound Ligand 
(III) 30 N/A 
(IV) 6000 N/A 
(V) 18 32 
(VI) 10 140 
 
Incorporation of these modified QDs into our conjugation strategy required a 
modification of the aforementioned Lewis acid-base coupling method.  The ampiphilic 
polymer used to encapsulate ITK-QdotsTM is terminated with poly-carboxylic acid 
residues; consequently ligands with a terminal amine can be covalently attached to the 
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QD surface via standard EDC coupling methodology.  Scheme 2 summarizes the 
synthetic approach by which a terminal amine was introduced on the alkyl linker arm of 
compound (VI).  A phthalimide protection scheme previously described by Wada et al. 
[104] allows for selective attachment of an alkyl chain to the parent para-amino GBR 
compound (from Scheme 1).  Subsequent removal of the phthalimide protecting group by 
treatment with hydrazine yielded compound (VII), an amine terminated derivative of 
compound (VI).  EDC coupling of compound (VII) to AMP-QDs, however, resulted in a 
reduced solubility of the QDs in buffer due to the increased hydrophobicity of the ligand.  
QD-conjugates of compound (VII) only remained water soluble in cases where the 
coupling reaction was performed to ensure minimal ligand coverage on the QD surface.  
A competitive uptake assay was then used to measure the relative activity of this 
compound and the IC50 for the free ligand (VII) was determined to be 5.7 nM.  Upon 
conjugation to the AMP-QDs, despite the solubility difficulties encountered, the IC50 was 
measured and found to be 1 nM relative to the QD concentration.  While this activity was 
an indication of improvement relative to previous conjugates, further modifications were 
still required to improve the overall stability of these probes and optimize the nature of 
their interactions with cellular targets. 
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Scheme 2. Synthetic approach to obtain modified GBR derivatives with a terminal amino functionality to 
allow selective ligand attachment to AMP-QDs. 
 
In order to address concerns regarding a diminished water solubility of these QD 
conjugates, compound (VII) was modified to include a poly ethylene glycol chain at the 
end of the alkyl chain. This modification acts to increases the water solubility of these 
conjugates as well as limit non specific interactions with cell surfaces due to a passivation 
of the AMP-QDs reactive surface [24].   Outlined in Scheme 3, this approach utilized a 
PEG linker which was first synthesized by the reaction of polyethylene glycol with 
phthalimide using conditions described by Mitsunobu [105].  The terminal hydroxy group 
of this modified PEG was then converted to a carboxylic acid moiety via a Jones 
oxidation with chromium (VI) oxide.  Attachment to the terminal amine of compound 
(VII) by means of an EDC coupling and subsequent removal of phthalimide with 
hydrazine yielded compound (VIII).  The IC50 value determined from the competitive 
32 
uptake assay for this free ligand was determined to be 80 nM, significantly more active 
than compound (IV), where the polyethylene glycol was directly attached to the parent 
GBR compound.  Continued experiments will eventually determine the biological 
activity of compound (VIII) conjugated to QDs. 
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Scheme 3. Synthetic modification of compound (VII) to incorporate a polyethylene glycol chain onto the 
alkyl linker facilitating improved QD water solubility while retaining biological activity. 
 
Fluorescent imaging applications utilizing small molecule-QD conjugates have 
proven to be elusive, however, despite continued optimization of these conjugates’ 
affinity for DAT.  It is now apparent that the presentation of small molecules on the QD 
surface must first be optimized in order to facilitate specific binding of the QD to a 
cellular target.  Incomplete surface modification, presumably caused by the steric bulk of 
large PEG derivatives or incomplete EDC coupling reactions, allows for albumin 
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adsorption to the reactive carboxylic acid functionality present on the QD surface.  
Albumin, a 66 kDa serum protein present in standard blocking solutions, has previously 
been shown to complex to reactive QD surfaces and facilitates QD endocytosis [14].  
Consequently, incomplete passivation of the QD surface with small molecule conjugates 
results in an endosomally associated fluorescent staining pattern consistent with QD-
albumin complexes (discussed in greater detail in Chapter 4).  This albumin adsorption 
presumably prevents the small molecules on the QD surface from interacting with DAT 
due to its added size and steric bulk.  Additionally, literature precedent seems to indicate 
that albumin absorption is less problematic in the case of bulkier antibody (~150 kDa) or 
streptavidin (~50 kDa) QD conjugates.  Continuing research will determine an optimized 
conjugation methodology for these small molecule QD conjugates, completely 
passivating the reactive QD surface, and incorporating a suitable linker to facilitate 
specific, high affinity interactions of these small molecules with DAT.  Despite the 
associated experimental difficulties of this approach, an optimized small molecule 
conjugation methodology will ultimately allow for a relatively low cost means of 
interrogating a wide variety of membrane bound cellular targets.  In addition to the 
dynamic, multiplexed, and single-molecule fluorescent imaging applications obtainable 
with QD fluorophores, this small molecule architecture would facilitate additional 
biological assays for drug discovery applications.   
While the focus of this section has been surface modification to specifically target 
DAT, a similar generalized approach can ultimately be used to develop QD-
nanoconjugates specific to any membrane bound cellular target.  The use of a functional 
assay to interrogate the relative activity of each intermediate allows for an improved 
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design of the molecular architecture required for an optimized interaction.  This approach 
has provided convincing evidence that an alkyl spacer is required to retain biological 
activity before attachment of PEGylated GBR derivative to the surface of a QD.  This 
seemingly subtle difference in ligands results in one full order of magnitude difference in 
biological activities.  Future studies will continue to use this approach to determine the 
optimal polyethylene glycol chain length and examine differences in ligand coverage for 
optimized small molecule-QD conjugates.   
 
Summary 
 
It is apparent that QDs have emerged as improved fluorophores for several biological 
imaging applications, and continued research will certainly provide further improvement 
of their scaffold-like architecture providing for sustained advances in fluorescence-based 
assays.  While it would be foolish to think they will ever completely replace traditional 
organic dyes and fluorescent proteins, they certainly can be utilized in conjunction with 
these existing technologies to access a more detailed understanding of cellular processes.  
Obviously, QDs provide an additional tool biologists can employ in certain applications 
to take advantage of their unique spectral properties.  Progress in truly multiplexed 
fluorescent assays utilizing QD probes will continue to provide an increasing amount of 
information regarding protein-protein interactions and cell signaling events.  Advances in 
temporal and spatial resolution, which has already been realized for dynamic imaging 
applications, will undoubtedly see additional development and continue to provide 
detailed information on receptor trafficking events at the single molecule level.  
Additionally, QDs possess a great deal of promise for numerous in vivo applications, 
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perhaps even the eventual design of combined diagnostic and therapeutic agents, 
allowing for targeted drug delivery in cancer treatment.  This chapter has presented 
several unique applications which clearly illustrate the remarkable promise QDs provide 
through their incorporation in biological imaging assays.  Hopefully, ongoing research 
and continued development will allow for an increased association of QDs in biological 
applications, and ultimately provide a more detailed understanding of numerous cellular 
processes. 
The remainder of this dissertation will detail my efforts to expand the utilization of 
QDs in a variety of biological imaging applications, with a particular emphasis on the 
development of small molecule QD conjugates to fluorescently label SERT expressed in 
mammalian cell cultures.  Chapter II details the pertinent experimental methods, 
materials and protocols which were developed and utilized throughout the course of this 
research.  Chapter III discusses initial imaging efforts which utilized antibody conjugated 
QDs to fluorescently label interleukin-2 receptor (IL-2R) expression in activated 
populations of Jurkat T cells.  This fluorescent assay utilized QD conjugates to verify the 
time-course associated with IL-2R translation and expression as well as investigate the 
trafficking of IL-2R subsequent to surface expression.  Chapter IV highlights several 
significant interferences which were unknowingly affecting the continued development 
of a small molecule targeting strategy based on an AMP-QD scaffold.  One such 
interferences involving the self-assembly of hydrophobic PEG derivatives to the AMP-
QD surface, initially demonstrated via electrophoresis and subsequently confirmed with 
1H-NMR spectroscopy, raises concerns regarding effective ligand presentation at the QD 
surface.  Additionally, it was further demonstrated that incomplete surface passivation 
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can lead to unwanted protein adsorption at the QD surface in the presence of serum 
blocking conditions, ultimately leading to an artifactual fluorescent staining in cellular 
assays.  Building upon this improved appreciation for potential interferences, the optimal 
labeling conditions for the fluorescent labeling of SERT expressed in mammalian cell 
cultures are then described in Chapter V.  This represents the first reported method to 
fluorescently assess SERT expression in mammalian cell cultures, either by fluorescence 
microscopy or flow cytometry, which takes advantage of the improved photophysical 
properties of the AMP-QD platform.  Furthermore, the importance of the length of the 
alkyl chain length which attaches the drug derivative to the PEG backbone has been 
highlighted, and an eleven carbon chain has proven to be suitable for labeling SERT.  
Finally, Chapter VI wraps up with a conclusion and summary of the research performed, 
while Appendix A details fluorescent imaging experiments performed to determine the 
localization of IDT307, a small molecule selectively transported by monoamine 
transporters. 
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CHAPTER II 
 
 
EXPERIMENTAL METHODS 
 
 
Surface Modifications to Introduce Biological Specificity 
Surface modifications are initially required in order to introduce specificity for any 
biological fluorescent application utilizing these QD conjugates. Numerous biomolecules 
have been utilized to generate biologically compatible QDs, and several approaches are 
available for QD conjugation and surface modification. Commercially available QDs 
from Invitrogen (formerly Quantum Dot Corporation) were used for the research reported 
herein, and surface modification generally involved antibody conjugation, biotinylated 
ligands, or covalent ligand attachment. Antibody conjugation (Chapter III) was 
performed using a commercially available QD antibody conjugation kit (Invitrogen) with 
IL-2Rα antibodies (R&D Systems). Covalent attachment of the antibody occurs through 
a maleimide coupling of a free thiol on the antibody to an amine functionality on the 
dot’s surface. Following antibody modification, QDs were separated from any 
unconjugated antibody by means of size exclusion chromatography and characterized by 
electrophoretic mobility and UV-Vis spectroscopy prior to their subsequent use in 
cellular assays. 
Small molecule attachment to the QD surface relied on either covalent modification 
of the QD surface or site specific ligand biotinylation for targeting streptavidin-
conjugated QDs.  Reactive ITK-Qdots™ (Invitrogen, formerly AMP-QDs from Quantum 
Dot Corporation) were utilized for the covalent attachment of specially synthesized 
amine-terminated poly(ethylene glycol) (PEG) ligands. Covalent attachment was 
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performed through the use of a 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDC) coupling reaction.  Optimized coupling conditions which result in 
PEG ligand attachment while retaining optimal fluorescent QD emission have been 
previously reported [24].  These optimized conditions were generally retained for QD 
conjugate preparation; however, in some instances the conjugation reaction was 
performed with a higher ratio of ligands in order to ensure complete QD surface 
coverage.  Consequently, EDC couplings were performed in borate buffer by the reaction 
of 2000-8000 molar equivalents of amine terminated ligand and 1500-6000 molar 
equivalents of both EDC and NHS for each molar equivalent of quantum dots.  The 
reaction was allowed to proceed for one hour with stirring at room temperature.  
Conjugates were purified from unconjugated ligand by size-exclusion chromatography 
(Sephadex G-50) and/or 100K molecular weight centrifugal filters (Millipore), and 
characterized by electrophoresis, UV-Vis spectroscopy and fluorescence spectroscopy. 
While the EDC coupling reaction is intended to result in a covalent attachment of the 
ligand’s terminal amine to a carboxylic acid on the polymeric QD coating, surface 
modification in the absence of added coupling reagents have also been demonstrated 
(Chapter IV).  For these self-assembly reactions, 8000 molar equivalents of ligand for 
each molar equivalent of quantum dot were stirred together in borate buffer for one hour 
at room temperature.  Surface modifications resulting from this approach cannot be due 
to covalent attachment, due to a lack of added coupling reagents.  Through the testing of 
a variety of PEG derivatives, each with differing terminal functionalities, it is apparent 
that this self assembly results from hydrophobic interactions with the QD surface. 
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Specific targeting utilizing biotinylated ligands to specifically target streptavidin-QD 
conjugates will also be discussed (Chapter V).  Direct conjugation of these ligands to the 
QD surface by means of the aforementioned EDC coupling reaction proved to be 
ineffective due to an apparent self-assembly of ligands to the QD surface, driven by the 
added hydrophobicity of the targeting terminus.  For these instances where direct surface 
modification proves unsuccessful, a two-step labeling approach taking advantage of the 
high affinity streptavidin-biotin interaction can be employed.  Biotin terminated PEG 
derivatives can first be incubated with cells expressing a desired cellular target, which 
allows the targeting terminus to initially seek out its intended target in the absence of 
QDs.  Streptavidin-conjugated QDs can then be employed to specifically seek out the 
biotin, effectively resulting in specific QD labeling without the need for ligand 
attachment to the QD surface.  This two-step labeling eliminates any interference due to 
the hydrophobic targeting functionality interacting with the QD surface.  Preconjugated 
QDs can also be prepared simply by mixing biotinylated PEG derivatives with 
streptavidin-QDs, with a subsequent purification from any unbound ligand, but generally 
resulted in diminished cellular labeling as compared to two-step labeling. 
 
Quantum Dot Conjugate Characterization Techniques 
 
Spectrophotometric Concentration Determination  
A determination of QD concentration was required for all QD-conjugates prior to 
their incorporation into cellular assays. QD concentrations were therefore determined by 
UV-Vis spectroscopy using a NanoDrop® ND-1000 spectrophotometer (Nanodrop 
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Technologies, Wilmington, DE).  This NanoDrop spectrophotometer requires only 2 μL 
of sample and does not use a cuvette for spectroscopic determinations, significantly 
reducing any potential loss of sample due to transfer to and from a cuvette. 
Concentrations were calculated from absorbance readings at 350 nm, 405 nm, 488 nm 
and 532 nm, each with a reported extinction coefficients [106], which were then averaged 
to yield a final concentration. 
 
Fluorescent Quantum Yield Determination  
Quantum yields were measured by comparing integrated fluorescence intensity of 
absorbance matched solutions using either a Carey Eclipse Fluorescence 
Spectrophotometer (Wright Lab) or an ISS PCI photon counting spectrofluoremeter 
(Chemistry Department Instrumental Lab).  In general, the Carey Eclipse instrument is 
rapid but less sensitive, while the ISS instrument is more cumbersome but provides 
increased sensitivity.  QD solutions as well as reference standard solutions were initially 
diluted to an identical optical density at a given excitation wavelength (~0.05 AU), 
ensuring that each solution has an identical absorbing power at the excitation wavelength.  
Generally, Rhodamine 101 in methanol (QY=0.95) with excitation 530 nm was employed 
as a reference standard for red emitting QDs, but alternate reference standards are 
certainly available.  The integrated fluorescent intensities were subsequently measured 
for both the sample and the standard, and the ratio of these values multiplied by the 
reported reference quantum yield gives the absolute sample quantum yield.  The added 
effect resulting from differences in refractive index can also be accounted for using 
equation (1). 
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Where Φ is the quantum yield, Int is the integrated fluorescent intensity, η is the 
solvent’s refractive index, st indicates the reference standard while x represents the 
sample being measured.  Quantum yield determinations provided a measure to assess any 
potential fluorescence quenching subsequent to surface modifications, a critical 
parameter to consider in developing fluorescent probes.   
 
Electrophoretic Characterization Techniques 
It is important to have methodologies to verify conjugation of biomolecules to the 
surface of the quantum dot, especially to confirm the presence of the biomolecule in the 
case that an initial cell labeling experiment fails. Further, in designing optimized probes, 
it is important to have a measure of biomolecule coverage. Too many biomolecules on 
the surface of the nanocrystal can lead to steric hindrance, while too few could reduce 
activity. Therefore, any surface modification to the QD surface was initially confirmed 
using agarose gel electrophoresis. All agarose gels were prepared at a concentration of 
1% agarose (Ultrapure™, Invitrogen) in Tris-acetate-EDTA (TAE) buffer, and run for 80 
minutes at a constant 80 volts in TAE running buffer.  Fluorescent images of all gels 
were acquired on an AlphaImager 2000 imaging station (Alpha Innotech Corp.).  Since 
surface modification acts both to passivate charged residues on the QD surface and 
increase the overall probe size, successful ligand attachment results in an overall 
reduction of the observed electrophoretic mobility. Consequently, PEG-QD conjugates 
exhibit a significantly reduced electrophoretic mobility in agarose gels, providing a clear 
demonstration of successful surface modification.   
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A non-denaturing polyacrylamide gel electrophoresis (PAGE) approach was 
developed to verify protein adsorption to the QD surface.  Since PEG-QDs already have a 
diminished electrophoretic mobility in agarose gels, any subsequent protein adsorption or 
antibody conjugation does not result in any appreciable difference to assess surface 
modifications. PAGE, however, provides the capability to initially separate QDs from 
any unadsorbed protein and subsequently stain to determine protein distribution.  Native, 
non-denaturing polyacrylamide gels were therefore prepared according to established 
protocols [107] utilizing a 2.5% polyacrylamide stacking gel with a 10% polyacrylamide 
resolving gel.  QD conjugates, with and without added albumin, were run at a constant 25 
mAmp for 2.5 hours.  A fluorescent image was then recorded using the AlphaImager 
2000 imaging station to verify location of QD bands present in the gel.  The gel was 
subsequently removed from it’s glass cassette and stained for protein distribution using a 
Commassie Blue staining solution overnight as per manufacturer’s instructions (Note: 
fluorescent images of the gel must be acquired prior to protein staining since the 
Commassie solution quenches the QD fluorescence).  A brightfield image following gel 
destaining provides a colorimetric determination of protein content throughout the gel.  
Protein adsorption to the QD surface is clearly resolved using this approach as it results 
in protein bands which co-localize with the previously observed QD bands.  
 
Fluorescamine Assay for Approximation of Ligand Loading  
Another way to determine the efficiency of biomolecule coupling to the nanocrystal is 
the fluorescamine assay [23, 24]. This assay is particularly useful if the functional group 
of the biomolecule being attached to the nanocrystal is an amine, which is often the case 
43 
when coupling biomolecules to carboxylic acid terminated dots. The general strategy of 
the assay is to determine the number of free amines both before and after the conjugation, 
with the difference being the conjugation yield and the number of biomolecules on the 
surface. After performing the coupling reaction, the unconjugated amine terminated 
ligand can be easily separated from the conjugated nanocrystals by means of a molecular 
weight cut-off filter. Quantification of this free ligand can then be performed by addition 
of an excess amount of fluorescamine (3 mg/mL in acetone), which forms a blue 
fluorescent species when reacted with an amine. Comparison of this fluorescent intensity 
(at 480 nm) to the fluorescent signal produced by the same number of ligands in the 
absence of coupling reagents allows the determination of the number of unreacted amines 
present, which is equivalent to the number of unconjugated ligands. The difference 
between the number of ligands added initially, and the number present after conjugation 
is therefore assumed to be the number of ligands that have been conjugated to the 
nanocrystals.   
 
Verification of Ligand Conjugation Using NMR Spectroscopy  
1H NMR experiments were performed to provide spectroscopic proof of QD-ligand 
complexes.  For these reactions, QD conjugation was carried out as before, with and 
without EDC coupling reagents, for two PEG derivatives (IDT319 and IDT320, 
described in greater detail in Chapter IV).  Following conjugation, the reaction mixtures 
were run through Sephadex G-50 columns to help eliminate any unconjugated PEG 
ligands, and only the fluorescent QD fraction was collected.  These QD solutions were 
then concentrated by means of 100K molecular weight centrifugal filters (Millipore), 
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with one added rinse to ensure complete removal of any unbound ligand, to a final 
volume of ~20 μL.  This concentrated QD solution was then diluted in deuterium oxide to 
a final concentration of 200 nM, and UV-vis absorption measurements were then made to 
ensure identical QD concentrations for each NMR sample.  All 1H spectra were then 
recorded on a Bruker 501 spectrometer at ambient temperature in D2O.  A small portion 
of the residual H2O signal was suppressed. The resulting spectra were analyzed using 
TopSpin 2.0 software.  
Control 1H NMR experiments for both free PEG derivatives and unconjugated AMP-
QDs demonstrated a lack of any spectral overlap (Figure 2-1).  The spectra of PEG 
ligands, as illustrated for IDT319 and IDT320 in Figure 2-1A, are dominated by a single 
peak at 3.64 ppm due to large number of chemically equivalent protons in their long PEG 
chains.  Unconjugated AMP-QDs (Figure 2-1B), on the other hand, presented no spectral 
feature at this chemical shift but instead had characteristic spectral features due to the 
protons present in their polymeric coating.  Consequently, this strong PEG signal at 3.64 
ppm served as a useful feature in providing spectroscopic characterization of ligand 
interactions with the QD.  Furthermore, the additional AMP-QD features provided an 
internal standard to normalize the integral area of this ligand peak to the amount of QDs 
in solution. 
 
45 
 
Figure 2-1.  Control 1H NMR spectra of free PEG ligands (A.) and unconjugated AMP-QDs (B) which 
demonstrate a lack of spectral overlap.  PEG derivatives consist predominately of a single peak at 3.64 
ppm, while no interfering peak is present in AMP-QD samples at this chemical shift. 
 
Cell Culture Protocols 
 
General Cell Line Maintenance and Subculture 
All cell cultures were maintained in accordance with recommended culture conditions 
and reagents as established by ATCC. As such, all cell lines were maintained in a sterile 
environment at 37 oC with 5% CO2, and standard aseptic techniques were followed for all 
cell maintenance protocols. Jurkat T cells (clone E6-1) were obtained from ATCC 
(ATCC #: TIB-152) and cultured in RPMI 1640 media supplemented with 10% fetal 
bovine serum (FBS) and either 10 mg/ml Ciproflaxin (Cellgro) or 100 U/mL penicillin 
with 100 U/mL streptomycin (Gibco).  Jurkat T cells reportedly have a doubling time of 
48 hours [108], and these cells should be subculture two to three times a week to 
maintain and optimal cell density between 1×105 and 1×106 viable cells/mL. Cultures 
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were maintained either by the addition of fresh medium or the complete replacement of 
medium to prevent the cell density from exceeding 3×106 cells/mL. Ideally, subculture 
should always be performed by centrifugation with subsequent resuspension at an initial 
seeding concentration of 1×105 viable cells/mL.  Half of the time, however, subculture 
simply involved transferring an aliquot of cells to fresh media based on approximated cell 
counts (assuming a 48 hours doubling time). Cell counts and centrifugation were 
employed at every other subculture interval to initially verify cell density and further to 
prevent accumulation of waste products present when transferring aliquots of old media. 
LLC-PK1 (ATCC#: CL-101) were obtained as a gift from the laboratory of Dr. 
Randy Blakely (Vanderbilt University) and cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 4.5 g/L glucose, 1.0 mM sodium pyruvate and 2 mM L-
glutamine, supplemented with 10% FBS, 100 U/mL penicillin, and 100 U/mL 
streptomycin. This epithelial cell line was initially isolated from a the kidney of a 
Hampshire pig [109] and has subsequently been employed in generating cells stably 
expressing the serotonin transporter (SERT) [110]. Both parent LLC-PK1 (untransfected) 
and stably transfected SERT-LLC-PK1 cells were maintained under identical conditions. 
Subculture of this adherent cell line was performed once cells reached 95-100% 
confluence, generally occurring two to three times per week depending on initial seeding 
density. Once cells reached 100% confluence, the media was aspirated from the culture 
flask to a waste container, and the cells were rinsed with either Ca/Mg free PBS or a 
trypsin/EDTA solution (since these cells tend to be quite adherent, a trypsin/EDTA rinse 
is preferred). Additional trypsin/EDTA solution was then added (3 mL for a T75 culture 
flask) and the culture vessel was transferred to the 37 °C incubator until the cells 
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completely detached from the plate (~ 5 minutes). Complete media was then added to in a 
three-fold excess as compared to initial trypsin/EDTA volume, to ensure complete 
neutralization of trypsin activity (i.e. 9 mL complete media for 3 mL trypsin/EDTA).  An 
aliquot of this cell suspension could then be deposited into a culture flask and diluted in 
an appropriate volume of fresh media.  A subcultivation ratio of 1:3 to 1:8 is 
recommended by ATCC, while a 1:6 split was generally sufficient for routine 
maintenance. 
HEK-293T cells (ATCC #: CRL-11268) were also supplied as a gift from the 
laboratory of Dr. Randy Blakely and were cultured in Modified Eagle’s Medium (MEM)  
containing 4.5 g/L glucose, 1.0 mM sodium pyruvate and 2 mM L-glutamine 
supplemented with 10% FBS, 0.1 mM MEM nonessential amino acids (Gibco), 100 
U/mL penicillin, and 100 U/mL streptomycin (Gibco). The 293T (293tsA1609neo) cell 
line is a highly transfectable derivative of the 293 cell line into which the temperature 
sensitive gene for SV40 T-antigen has been inserted [111]. Subculture of these cells was 
generally performed two to three times per week, at 90-95% confluence.  Once the cells 
were reached the desired confluence, the media was aspirated off and a trypsin/EDTA 
solution was added (3 mL for T75 culture flask) to induce cell dissolution at 37 °C.  
(Note: no rinsing step after media aspiration was required as these cells are much less 
adherent than the previously described LLC-PK1 cultures.) After the cells have lifted off 
the plate, a three fold excess of complete media was then added to neutralize and residual 
trypsin activity, and an appropriate aliquot of cells were then transferred to a new culture 
flask and diluted with fresh media.  ATCC recommends a subcultivation ratio of 1:4 to 
1:8, and a 1:6 split was generally employed for these studies. 
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Inducing IL-2R Expression in Jurkat T Cells 
An initial research effort was focused on the development of QD-conjugates capable 
of specifically labeling activation products in populations of T cells (Chapter III).  One 
common membrane-associated receptor associated with T cell activation, interleukin-2 
receptor (IL-2R), was chosen as a cellular target for initial experiments to demonstrate 
specific QD labeling. Unactivated T cells, which do not express IL-2R, consequently 
provide a suitable negative control to verify specificity of QD labeling. IL-2R expression 
was chemically induced by exposing populations of Jurkat T cells to the activating agents 
phorbol myrastoyl acetate (PMA) and ionomycin. Consequently, unactivated Jurkat T 
cells were initially seeded in 8 separate flasks at an initial density of 1×105 cells/mL in 
complete media. Every 12 hours following seeding, a single flask of cells was activated 
by addition of 10 nM PMA and 4 μM ionomycin such that after 84 hours there was a set 
of eight flasks of cells each exposed to 0 (control), 12, 24, 36, 48, 60, 72, and 84 hours of 
the activating agents, respectively. After 84 hours, the cells were counted, centrifuged, 
and supernatants collected (immediately frozen at –20 oC for later ELISA analysis). Cells 
from each time point were then used immediately for all subsequent QD labeling 
experiments. It is important to note that freshly prepared solutions of PMA and 
ionomycin are critical to induce successful activation. PMA degrades rapidly in aqueous 
environments, but aliquots stored at -80 oC will not undergo degradation as rapidly. 
Consequently, 1000×stock solutions of both PMA and ionomycin were freshly prepared, 
aliquoted out into individual bullet tubes, and stored at -80 oC prior to their use. At each 
activation time point, individual bullet tubes of PMA and ionomycin stock solutions were 
thawed and used immediately, while any excess reagent was subsequently disposed of.  
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This procedure routinely resulted in successful demonstrations of controllable Jurkat T 
cell activation. 
 
ELISA Approach for Measuring Secretion of IL-2 
Successful T cell activation initiates a cascade of cellular processes which eventually 
result in the expression of cellular activation products.  IL-2R expression is accompanied 
by secretion of IL-2, which acts in an autocrine fashion to promote proliferation and 
clonal expansion of antigen-specific T cells [112].  Therefore, the presence of IL-2 in the 
supernatants T cell populations, following exposure to PMA and ionomycin, would 
provide an indicator of successful activation, and verify controlled expression of cellular 
activation products. Consequently, supernatants from each time point were analyzed 
using a Quantikine® ELISA (R&D Systems) specific for IL-2 in order to quantify the 
amount of IL-2 secreted following activation. This assay employed a microplate which 
was pre-coated with monoclonal antibodies specific for IL-2.  Standards and samples 
were incubated in these wells, and any IL-2 present was bound by the immobilized 
antibody. An enzyme-linked polyclonal antibody specific for IL-2 was subsequently 
added to each well after washing away all unbound substances. After additional washing 
to remove any unbound antibody-enzyme reagent, a substrate solution was added to each 
well and color develops in proportion to the amount of IL-2 bound in the initial step. This 
development was stopped, and the absorbance at 450 nm was measured by UV-Vis 
spectroscopy using a Bio-Tek Synergy-HT plate reader (Wright Lab). Calibration of 
optical densities to standard samples of known concentrations consequently permits a 
straightforward quantification of IL-2 present in cellular supernatants. 
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 Plasmid DNA Expansion and Purification 
Transfection is the process by which foreign DNA is introduced intracellularly as a 
means to induce desired protein expression [113]. Plasmid DNA encoding for both SERT 
and DAT in a pcDNA3.1 vector (as previously described [110]), were initially supplied 
as a gift from the laboratory of Dr. Randy Blakely. Expansion of these initial stocks was 
eventually performed as a means of generating an independent supply of plasmid DNA 
for all subsequent transfections. As such, competent DH5α E. coli cells (Molecular Cell 
Biology Resource Core, Vanderbilt) were initially incubated with 1 μL of plasmid DNA, 
and then placed at 42 oC for 30 seconds to induce the transformation bacteria, inducing 
them to take up exogenous plasmid. These heat shocked cultures were subsequently 
streaked onto ampicillin-selective agar plates and stored overnight at 37 oC.  As the 
pcDNA3.1 vector incorporates an ampicillin resistance region, only those E. coli cells 
which have taken up plasmid will be able to survive under the selective pressure of 
ampicillin. Bacterial cultures for plasmid preparation were then grown from a single 
colony picked from this selective agar plate, and deposited directly into 125 mL of LB 
medium containing ampicillin (Gibco). These cultures were then expanded overnight at 
37 oC with vigorous shaking, owing to a logarithmic-phase bacterial growth. Following 
this expansion, purification of plasmid DNA was then performed using a plasmid midi kit 
(Qiagen), which employs alkaline lysis to initially extract plasmid from bacterial cultures 
and an anion-exchange column for subsequent purification. Spectroscopic determination 
of plasmid concentration was then performed using a NanoDrop spectrophotometer. All 
plasmid DNA was subsequently stored in Tris-EDTA (TE) buffer at 4 oC prior to use. 
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Transient Transfection to Induce Protein Expression 
Initial research efforts in developing QD conjugates to specifically interact with 
biogenic amine transporters generally employed stably transfected cell lines expressing a 
protein of interest. Uncertainty with regards to transporter expression levels in these 
stable lines after routine subcultivation, however, led to the use of transient transfection 
as a means of generating cells with substantially increased transporter expression. While 
stable transfections generally involve a chromosomal DNA integration event, protein 
translation from transient plasmid DNA transfection occurs independent of host cell 
chromosomal influences, which can ultimately provide higher expression levels. While 
numerous transfection reagents and conditions are commercially available, four such 
reagents were initially tested in an effort to elucidate optimal transfection conditions to 
induce either SERT or DAT expression. HEK-293T cells were therefore transfected with 
SERT plasmid DNA according to manufacturer’s recommended conditions for 
Lipofectamine 2000, Lipofectamine LTX with Plus reagent, Lipofectamine LTX without 
Plus reagent (all from Invitrogen), and Fugene HD (Roche). These cells were then 
assayed for SERT expression 48 hours after transfection using IDT307, a small molecule 
which is intracellularly fluorescent and selectively transported by monoamine 
transporters (discussed in greater detail in Appendix A). Consequently, successful 
expression of SERT results in an observable intracellular green fluorescence upon 
exposure to IDT307, while no such fluorescence is present in the absence of SERT 
expression. Fluorescent imaging results for each transfection reagent are illustrated in 
Figure 2-2. These data indicate that the Lipofectamine 2000 transfection resulted in the 
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highest expression of SERT, while transfection efficiencies for each of the alternate 
reagents are greatly diminished.  
 
Figure 2-2.  Identifying an optimal transfection reagent to induce expression of SERT. IDT307 fluorescent 
images (top row) and bright field composite overlay images (bottom row) to assess SERT expression 
following transfection with four commercially available transfection reagents (as indicated on top). As 
IDT307 is selectively transported intracellularly by monoamine transporters; its characteristic green 
fluorescence is indicative of SERT expression.  Lipofectamine 2000 results in the highest transfection 
efficiencies for the expression of SERT in HEK-293T cells. 
 
Lipofectamine 2000 was therefore utilized in all subsequent transfections as a means 
of inducing the highest possible expression of SERT. Transfections were performed in a 
24 well plate format and utilized 0.8 μg plasmid DNA and 2 μL Lipofectamine 2000 per 
well, as per manufacturer recommendations. Control populations of cells lacking 
monoamine transporter expression were generated by transfection of empty pcDNA3.1 
vector. These ‘sham-transfected’ cells provided an improved negative control for cellular 
assays as compared to non-transfected cells, and eliminated any potential experimental 
interference resulting from exposure to transfection reagents. Transfections were 
performed at a confluence of ~90% and transporter expression was assayed 48 hours 
following transfection to ensure sufficient time for successful translation and expression. 
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Assessing Monoamine Transporter Expression with IDT307 
Cellular assays dependent upon monoamine transporter expression have undoubtedly 
benefited from the discovery of IDT307, a small molecule first synthesized in the 
Rosenthal research group which is selectively transported by monoamine transporters. 
IDT307 provides a non-isotopic means of assessing transporter expression owing to its 
unique intracellular fluorescent characteristics (discussed in greater detail in Appendix 
A). IDT307 was therefore utilized prior to any fluorescent imaging experiments as a 
means of verifying successful monoamine transporter expression, saving time and 
reagents as well as eliminating any associated uncertainty in experimental design. A 
straightforward assay to verify successful transporter expression simply involved the 
addition of IDT307 directly to the culture media at a final concentration of 5 μM, and 
incubating at 37 oC for five to ten minutes. Fluorescent images using a standard GFP 
filter set were then acquired immediately, and successful transporter expression was 
evident by an observable increase in intracellular fluorescence.  No additional rinsing was 
required since IDT307 is only fluorescent in an intracellular environment, and any excess 
IDT307 in solution did not result in any observable fluorescent background. 
 
Quantum Dot Labeling Protocols 
Initial QD labeling experiments utilized IL-2Rα antibody-conjugated QDs as a means 
of specifically interrogating IL-2R expression in activated Jurkat T cells. This labeling 
protocol utilized centrifugation as a means of transferring these suspension cells from cell 
culture to various labeling and rinse solutions. Consequently, at selected time points 
following activation, a population of cells was initially centrifuged using a table top 
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microcentrifuge for 5 min at 1500 rpm to pellet the cells and permit removal of the cell 
culture media. This cell pellet was then resuspended in 100 μL of 10 nM anti-IL2Rα-
conjugated QD in PBS for 30 minutes on ice. Unbound QDs were subsequently removed 
by centrifugation, with one additional rinse in cold PBS, and labeled cells from each time 
point were then divided into two populations: 5×105 cells were resuspended in media 
containing 10% FBS and 1 nM Yopro-1 (Cell viability indicator, Molecular Probes) for 
fluorescent imaging analysis and the remaining cells were resuspended in PBS with 2% 
FBS and 1 nM Yopro-1 for flow cytometry analysis. This labeling protocol resulted in 
sensitive detection of IL-2R expression due to a diminished fluorescent background from 
unbound QDs and minimal nonspecific cellular interactions. 
Demonstrating specific labeling of SERT with small molecule-conjugated QD probes 
was the primary aim of this research project, and numerous labeling protocols were tested 
in an effort to specifically interrogate this target. All labeling protocols therefore 
employed two negative control populations to demonstrate specificity: (1) a parental cell 
line lacking receptor expression, and (2) a receptor-expressing population pre-blocked 
with an inhibitor specific to the intended target. These negative controls would ultimately 
permit an assessment of whether any observed QD labeling was the result of nonspecific 
cellular interactions, or the result of specific interactions with an intended target. While 
specific labeling parameters such as QD concentration, incubation time and temperature 
have to be optimized for each particular protocol, some general conclusions can be made 
to expedite the development of future QD labeling protocols. Firstly, QD concentrations 
of 1-10 nM have proven to be sufficient for numerous fluorescent imaging applications, 
and should provide a useful starting point for subsequent labeling protocols.  Secondly, it 
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is important to determine the effect of incubation temperature for the development of an 
optimized labeling protocol. Generally, incubation at 37 °C permits membrane cycling 
and receptor trafficking, while these processes are significantly slowed by incubation on 
ice at 4 °C. Subsequent labeling efforts could therefore be initially performed at 4 °C to 
slow any receptor internalization processes and maintain receptor expression at the cell 
surface. Additionally, all efforts should first be made to verify successful receptor 
expression before blame is placed on the QD probe for ineffective labeling. Finally, while 
the inclusion of blocking agents such as BSA or serum could dramatically reduce any 
observed fluorescent background labeling, care should be taken to avoid any potential 
artifactual labeling due to unintended protein interactions with the QD surface.  
Cellular labeling studies were eventually performed to verify the artifactual 
fluorescent response caused by protein adsorption to the QD surface (Chapter IV). These 
studies examined the different responses two chemically similar PEG derivatives had on 
cellular assays. For these experiments, LLC-PK1 cells (both parental and SERT-
expressing) were initially plated in MatTek 35 mm culture dishes with a cover-glass 
bottom (to permit high magnification imaging with oil immersion optics). QD labeling 
was performed once the cells reached ~95% confluence, following an initial incubation in 
a blocking solution of 2% BSA and 10% horse serum in KRH buffer for 30 min. This 
high serum blocking solution was utilized as an effort to completely block nonspecific 
binding sites and eliminate any background QD fluorescence. Cells were then exposed to 
5 nM QD solutions, either IDT319 conjugated QDs or IDT320 conjugated QDs diluted in 
the same 2% BSA and 10% horse serum in KRH buffer, for 30 min at 37 °C. The cells 
were rinsed three times with cold KRH buffer and immediately imaged on a widefield 
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fluorescent microscope at 100× magnification. This protocol resulted in a non-uniform 
cellular labeling for the IDT319 conjugates, while no significant QD labeling was 
observable for the IDT320 conjugates. Several different labeling conditions were then 
investigated in an attempt to elucidate the underlying cause of IDT319 QD conjugate 
labeling. Labeling at 4 °C eliminated any intracellular fluorescent labeling, indicative of 
an active transport mechanism following QD labeling. Cells which had been serum 
deprived prior to QD labeling had a much higher and uniform fluorescence, indicative of 
a cell cycle dependence. Attempts to block fluorescence labeling with excess free 
IDT319 seemed to indicate that the labeling was not receptor-mediated, and changing the 
blocking solution to 5% BSA without horse serum did not cause in any difference. A 
similar labeling pattern was also observed with HEK-293 cells, demonstrating that this 
phenomenon was not unique to LLC-PK1 cells. Eventually, QD labeling attempts with 
unmodified AMP-QDs reproduced the same fluorescent labeling result, ultimately 
leading to the conclusion that protein interactions at the QD surface were in fact the cause 
of the observed cellular interactions. 
A principle observation from this protein adsorption investigation was that the added 
hydrophobicity of the SERT-selective region of IDT320 was in fact causing this ligand to 
self-assemble to the QD surface. This immediately raised concern over the effectiveness 
of ligand presentation at the AMP-QD surface; if the targeting region was interacting 
with the QD surface then it would not be able to specifically interact with an intended 
biological target. A two-step labeling approach using biotinylated PEG derivatives, 
altogether eliminating the necessity of ligand presentation at the AMP-QD surface, 
eventually proved to be effective. Nevertheless, care must be taken in subsequent labeling 
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protocols to optimize ligand presentation at the QD surface, especially for increasingly 
hydrophobic targeting functionalities on PEG derivatives. Another observation from 
repeated cellular imaging studies was that background QD fluorescence predominately 
occurs on the culture vessel surface, and no amount of rinsing was effective at 
eliminating this background. Furthermore, minimal QD nonspecific interactions were 
observed when labeling cells in suspension, even without serum protein blocking. The 
added background fluorescence due to QD interactions with the surfaces of the culture 
vessel was eventually eliminated by labeling the cells in suspension. 
These observations eventually culminated in the development of a specialized two-
step labeling protocol for the specific targeting of SERT with small molecule QD 
conjugates. In this assay, HEK-293T cells, transiently transfected to express SERT, were 
incubated with 1 μM biotinylated ligand (IDT318) in PBS for one hour at 37 °C.  Cells 
were subsequently labeled in suspension, following dissolution from the plate with 0.05% 
trypsin-EDTA (Gibco), in order to minimize any background QD fluorescence due to 
nonspecific QD interactions with the plate.  The cells were pelleted after dissolution from 
the plate by centrifugation to eliminate any free ligand and then resuspended in 2.5 nM 
streptavidin-QDs in PBS for 5 minutes at 4 °C.  Labeled cells were then rinsed three 
times by centrifugation and resuspension in cold PBS and assayed for QD fluorescence 
immediately. While these parameters were initially derived from successful imaging in an 
oocyte model, subsequent analyses were performed to determine optimal ligand 
concentration and incubation time (Chapter V).   
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Widefield Fluorescent Microscopy 
Widefield fluorescent images were obtained using a custom-built Zeiss Axiovert 
200M inverted fluorescence microscope equipped with a Cool-SnapHQ2 (Photometrics 
Corp.) electrically cooled CCD camera. Initially, this microscope was equipped with a 
Zeiss Axiocam color digital camera which was eventually replaced due to inadequate 
sensitivity and resolution. The Cool-SnapHQ2 is a monochrome alternative which 
provides superior detection sensitivity, routinely capable of detecting single QD blinking 
events. The microscope currently has 5×, 10×, 20×, 40×, and 100× objectives, each with 
the necessary optics to permit differential interference contract (DIC) imaging. The 100× 
objective is an oil-immersion lens with a working distance of 0.17 mm, limiting its use 
solely to samples prepared on glass coverslips; all other objectives should not come in 
contact with immersion oil, therefore transitioning from 100× to lower magnification 
without first cleaning any oil from the sample is strictly prohibited. A HBO 103 
mercury short-arc lamp provides broad-spectrum excitation illumination for fluorescent 
imaging, and a five position reflector turret facilitates multi-channel fluorescent 
detection. Consequently, as many as four different fluorescent images can be acquired in 
rapid succession, with the fifth turret position devoted to DIC (brightfield) detection. The 
entire system is interfaced with a Pentium 4 workstation running Metamorph image 
acquisition and analysis software (Molecular Devices) which is capable of automating 
basic functions for efficient operation of both the microscope and the camera. 
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Zeiss Axiovert 200M Inverted Fluorescent Microscope Operation 
This section is meant to provide a general procedure for image acquisition using the 
Axiovert 200M inverted fluorescent microscope, while more detailed instructions can be 
found in the operating manual (kept in the lab with the microscope). The HBO-103 
power source should always be the first component turned on and the last component 
turned off, to avoid any potentially destructive interference which could affect 
workstation operation. The remaining system components (except the camera) can be 
turned on once the lamp indicator light switches on. If this lamp indicator light remains 
off, the HBO-103 W/2 bulb has burnt out and needs to be replaced. Specific instructions 
for replacement of this bulb are described in the operating manual, but one bulb should 
provide ~300 hours of operation. The camera should then be turned on only after the 
computer has completed its startup operations. Once all system components are powered 
up, double-click the Metamorph desktop icon to open the image acquisition software. A 
common error reported upon starting Metamorph indicates that no cameras are available. 
If this message is displayed, exit out of Metamorph, turn the camera off and then back on, 
and restart Metamorph. This should allow the computer to recognize the camera, but this 
message can generally be avoided by only turning the camera on after the computer has 
completely booted up.  
Once Metamorph has initialized, critical parameters for image acquisition can be 
controlled through the ‘Acquire’ dialogue box. The ‘show live’ button initializes a live 
video stream from the camera useful for focusing and identifying regions of interest. If no 
signal is observable for the live stream, it is probable that the light path has not been 
directed to the camera. The Left/Right button on the (middle button on the lower left side 
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of the microscope) directs the light path to one of three orientations: 100% to binoculars, 
100% to camera, or 50/50 binoculars/camera. The default setting is 100% to binoculars 
upon startup, and depressing the button twice will direct 100% of the light to the camera. 
With the light now directed to the camera, and a live video of your sample displayed on 
the monitor, settings such as exposure time and binning can be set in the ‘Acquire’ 
dialogue box.  It is also possible to switch between illumination settings by selecting the 
appropriate fluorophore from the ‘Settings’ drop-down menu in the ‘Acquire’ dialogue 
box. Selecting a fluorophore from the ‘Settings’ menu causes the reflector turret to rotate 
placing a fluorescent filter set in the light path. It is important for the user to verify that 
the appropriate filter cube is in place. Since multiple users utilize this system, filter cubes 
are frequently swapped out, so care must be taken to ensure the correct placement of the 
appropriate filter cube. To maintain some order regarding filter placement, the following 
placement scheme has generally been utilized: Position 1, DIC; Position 2, DAPI or 
white light; Position 3, QD605 or TRITC; Position 4, QD655; and Position 5, GFP. 
Therefore, a user attempting to acquire a TRITC fluorescent image will first have to 
verify that the appropriate TRITC filter set is in position 3 to ensure accurate image 
acquisition. Once the appropriate filter set is in place and all settings have been 
established, simply click the ‘Acquire’ button to collect the appropriate image.  
The Metamorph software package also provides numerous useful image analysis tools 
in addition to image acquisition capabilities. The ‘scale image’ and ‘overlay images’ 
commands in the ‘Display’ toolbar are likely the most widely used commands. Generally, 
fluorescence microscopy is utilized to demonstrate differences in fluorescent intensity of 
one sample as compared to a control sample. The ‘Scale image’ command allows the user 
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to establish uniform scales to permit straightforward sample-to-sample comparisons, 
assuming of course that identical acquisition conditions were used to obtain each image. 
The ‘overlay images’ command is useful for overlaying a fluorescent image onto a 
corresponding brightfield image or for demonstrating colocalization of two fluorescent 
images. Additionally, a calibration bar can be superimposed onto an image by selecting 
‘Calibration Bar’ from the graphics menu in the display toolbar. One final problem 
frequently encountered has to do with opening these image files with programs other than 
Metamorph. Metamorph image files have a large bit-depth and are encoded so that they 
can only be opened in Metamorph. The ‘Duplicate as displayed’ command under the 
‘Edit’ toolbar can be used to create a lower resolution 8-bit image which can be opened 
by all other image editor programs (or cut and paste directly into MS Office 
applications). It is still important, however, to retain the original Metamorph file for any 
subsequent analysis, because a significant amount of information (bit-depth) is lost upon 
this conversion to an 8-bit image. 
 
Confocal Fluorescent Microscopy 
All confocal image analyses were performed on a Zeiss LSM 510 Meta imaging 
system available through the Vanderbilt Cell Imaging Shared Resource (CISR). While all 
users of this microscope facility must first complete a short training course, it is available 
to researchers at Vanderbilt University for a nominal hourly charge. The system is 
equipped with an argon ion laser and two HeNe lasers capable of excitation at 458 nm, 
477 nm, 488 nm, 514 nm, 543 nm, and 633 nm. Single color QD analysis generally 
utilized excitation at 488 nm, with an appropriate band pass filter for fluorescent 
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detection using a photomultiplier tube (PMT). Dual color fluorescent images 
incorporated either single or dual channel excitation with appropriate dichroic mirrors, 
band pass filters, and long pass filters in place to ensure negligible fluorescent bleed-
through between channels. Appropriate single color control samples were always 
examined as a means to assess and eliminate any cross-talk between fluorescent channels. 
Generally, routine day-to-day fluorescent imaging analyses were performed using the 
widefield fluorescent microscope, while the confocal microscope was used more 
sparingly as a means of verifying intracellular localization or generating higher quality 
images. 
 
Flow Cytometry 
Flow cytometry analysis provides a convenient means to rapidly assess individual 
cellular fluorescence and demonstrate specific QD labeling for populations of cells in 
suspension. These analyses were initially performed to verify specific labeling of 
activated Jurkat T cells (a suspension cell line) using fluorescence activated cell sorting 
(FACS) analysis, then performed on a Becton Dickinson FACStar+ cell-sorter. This 
approach successfully corroborated the fluctuations in fluorescence intensity throughout 
the time course of activation, initially observed using microscopy. Eventually, successful 
labeling of SERT was demonstrated for suspensions of transiently transfected HEK-293T 
cells, and flow cytometry was once again employed to corroborate fluorescent imaging 
data, this time using a BD LSRII flow cytometer. All flow cytometry analyses were 
conducted with the equipment and assistance of the VMC Flow Cytometry Shared 
Resource. All analyses employed discrimination gates based on scatter parameters to 
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ensure interrogation of only viable, single cells. A typical gating approach is presented in 
Figure 2-3, and illustrates how scatter parameters can be utilized to identify specific 
populations of individual viable cells. Histograms displaying the number of cells at a 
given QD fluorescence intensity were then generated using BD FACSDiVaTM software. 
This approach has proven to be faster and more efficient than fluorescent microscopy at 
determining fluorescent intensity for populations of cells in suspension. Microscopy, 
however, is still preferable for analysis of adherent cell cultures and for visualizing 
dynamic cellular processes. 
 
 
Figure 2-3. Gating individual, viable cells using scatter parameters from flow cytometry data. An initial 
population of viable cells is initially identified from a plot of front scatter area versus side scatter area (left). 
This population is then displayed with regards to side scatter width versus height (middle) and an additional 
gate is established to discriminate single cell events from multiple events. Finally, this population is plotted 
as a function of front scatter height versus width (right) and a final gate further discriminates individual 
cellular events.  
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CHAPTER III 
 
 
QUANTUM DOT ANTIBODY CONJUGATES FOR MONITORING  
THE DYNAMICS OF IL-2R EXPRESSION [114] 
 
 
Introduction 
In this chapter the feasibility of using QDs as nanoprobes for Thymocyte (T cell) 
signaling events is examined, with the intention of demonstrating the benefits of 
incorporating QDs as a major read-out component of a proposed T cell based cell-
signaling platform.  To date, there have been a limited number of imaging applications 
which interrogate a dynamic cellular response utilizing QDs despite their improved 
photostability.  An initial dynamic imaging application employed non-targeted, endocytic 
loading of QDs into both mammalian and D. discoideum cell lines and confirmed no 
deleterious effects on cellular physiology [16].  Single quantum dot tracking methods 
have since been used to elucidate diffusion dynamics of glycine receptors in the neuronal 
membrane over time frames ranging from seconds to minutes [34].  More recently, QDs 
were used to demonstrate retrograde transport of epidermal growth factor receptors and 
track their subsequent endosomal trafficking [29].  Peptide-conjugated QDs have also 
been used intracellularly, following transfection, for imaging nuclear targets allowing 
visualization of the transport of the QDs from the cytoplasm to the nucleus [44].  It is 
apparent that QDs, given their unique optical properties, may ultimately allow for 
unprecedented temporal resolution for imaging dynamic cellular processes. The research 
described in this chapter utilizes antibody conjugated QDs to interrogate the signaling 
dynamics of T cell activation, providing a clear demonstration of their improved dynamic 
imaging capability. 
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T cell Activation and the Adaptive Immune Response 
The immune system of mammalian organisms responds to antigenic challenges 
utilizing both innate and adaptive immune responses. Innate immunity provides 
immediate defense against infection either by preventing microbial entry or by 
recognizing conserved antigens expressed on microbes, such as lipopolysaccharide 
(LPS). This innate immunity initially relies on epithelial barriers to prevent microbial 
entry, but also employs circulating effector cells (i.e. neutrophils, macrophages and NK 
cells), circulating effector proteins (complement, mannose-binding lectin, C-reactive 
protein) and cytokines to illicit an immediate immune response. The adaptive immune 
response, however, results from cellular recognition of a pathogen with subsequent clonal 
expansion and proliferation to produce an antigen specific response. Consequently, the 
adaptive immune response is much slower as compared to the innate response, but the 
additional specificity and diversity ensures an overall improved immune function. T cells 
are the major signal transducers of the adaptive immune response in mammalian systems. 
Acting in concert with antigen presenting cells, T cells are capable of recognizing an 
incredibly wide variety of distinct antigens and provide enhanced responses to repeated 
exposures to the same antigen. T cells coordinate the adaptive immune response through 
cytokine signaling to promote the destruction of microbes residing in phagocytes, 
stimulate B cells to secrete antibodies, or even direct the killing of infected cells in order 
to eliminate potential reservoirs of infection. This is not to say, however, that the innate 
and adaptive immune responses act independent of one another, but, rather, are both 
components of an integrated cooperative system of host defense [112]. 
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Signaling Pathway of T cell Activation  
In the presence of a perceived threat, T cells undergo a process of activation and 
proliferation to coordinate an antigen specific immune response. Cell surface expression 
of the cytokine receptor interleukin-2 receptor-α (IL-2Rα) in T cells, as well as secretion 
of the cytokine interleukin-2 (IL-2), is widely used as an indicator of T cell activation 
[112]. Figure 3.1 illustrates the major signaling pathways leading to IL-2 and IL-2Rα 
production. Successful engagement of the T-cell receptor (TCR) by antigen presenting 
cells (APCs) results in a cascade of intracellular events including the DAG 
(diacylglycerol), IP3 (inositol 1,4,5-triphosphate), and MAPK (mitogen-activated protein 
kinase) pathways. Activation of phospholipase C (PLCγ1) by adaptor proteins and ZAP-
70 results in the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) to produce IP3 
and DAG. IP3 binds to the endoplasmic reticulum and releases calcium stores, activating 
transcription factor NFAT (nuclear factor of activation in T cells), which then moves to 
the nucleus. The recruitment and activation of protein kinase C (PKC) by DAG [112] has 
been shown to be integral to the activation of both NFκB (nuclear factor kappa beta) 
[115] and AP-1 [116, 117]. Alternatively, T cell activation can be chemically induced in 
vitro by treatment with phorbol myrastoyl acetate (phorbol ester or PMA) and ionomycin, 
which act together to upregulate NFAT, NFkB, and AP-1 [118]. Once in the nucleus, the 
transcription factors NFAT, NFκB, and AP-1 act in concert to coordinate the activation 
of several genes involved in host defense and inflammatory responses, including 
production of IL-2 and expression of IL-2Rα. 
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Figure 3.1  Signaling pathway associated with T cell activation.  Engagement of the TCR and coreceptors 
by an APC results in a signaling cascade producing transcription factors NFAT, NFκB, and AP-1 required 
for successful activation of the T cell and expression of IL-2 and IL-2Rα. As indicated, chemical 
stimulation can occur by treatment with PMA and ionomycin. PMA activates PKC initiating the signaling 
cascades responsible for the transcription of AP-1 and NFκB, while ionomycin causes a release of 
intracellular calcium stores resulting in transcription of NFAT.  Thus, treatment with both PMA and 
ionomycin upregulates all three transcription factors required for successful activation and expression of 
IL-2Rα and IL-2. 
 
Interrogating Protein Expression as a Means of Elucidating Toxin Exposure 
This high level of complexity and discriminatory ability within the signaling 
pathways of T cells not only allows these cells to be highly effective for mediating 
immune responses against novel pathogens, but may also permit the cells to be utilized as 
biosensors to gain insight into methods of detection, prevention and treatment for 
biological warfare agents. Construction of a detection system with the ability to sense 
novel pathogens of both known and unknown pathogenesis could be accomplished by 
utilizing T cells as biosensors and taking advantage of the discriminatory power of their 
diverse intracellular signaling pathways. Previous studies support the feasibility of this 
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premise as both anthrax toxin [119] and immunomodulatory agents [120] have been 
shown to suppress T cell activation with a significantly varied response on cytokine 
production levels. Platforms to study signaling dynamics of single T cells and other cells 
by utilizing technology that allows the simultaneous detection of multiple signals in live 
cells are currently in development [121]. Additionally, it would be desirable to detect 
signaling on an individual cell basis to avoid averaging out either rare but important 
signaling events or spatial and relational correlations of signaling events with regard to 
the overall signaling cascade. Incorporation of QDs in this platform will ultimately allow 
for the interrogation of multiple pathways given their narrow fluorescent emission 
spectra, while the inherent brightness of QD probes provides an improved chance of 
detecting the limited amounts of cytokine production at the level of a single cell. Finally, 
their intrinsic photostability permits further investigation into the temporal dynamics of 
receptor expression and subsequent localization following expression. 
 
Results and Discussion 
 
 
Time-Course of IL-2R Expression 
Initial research efforts were necessarily focused on demonstrating specific labeling of 
IL-2R using QDs conjugated to an antibody specific to IL-2Rα (see complete 
experimental details in Chapter 2). For these fluorescent imaging assays, Jurkat T cells 
were initially activated by treatment with both PMA and ionomycin to induce expression 
of IL-2R. These activated cells were subsequently incubated with antibody-conjugated 
QDs to assess IL-2R expression at various time points following activation. A green 
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fluorescent cellular viability indicator, YOPRO-1 (Invitrogen Corp., Carlsbad CA), was 
included in the final rinse solution to eliminate any potential fluorescent artifact labeling 
resulting from nonspecific QD interactions with dead cells.  Representative fluorescent 
images obtained at 0, 12, 18, 32, 48, 60, 72, and 84 hours following activation are 
illustrated in Figure 3.2. Minimal QD fluorescence is observed in unactivated cell 
populations (0 hour time point) due to a lack of basal IL-2R expression, therefore this 
population of cells provides a suitable negative control to demonstrate specific labeling. 
The QD fluorescence observed at later time points is indicative of maximal IL-2R 
expression following 32-48 hours of activation, consistent with previous reports of IL-2R 
transcription and translation [112].  Consequently, these antibody-conjugated QDs 
provide a useful tool to specifically interrogate the dynamics of receptor expression. 
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Figure 3.2  Fluorescent microscopy experiments demonstrating T cell activation.  Fluorescent images 
(bottom) and bright-field composite overlay images (top) of QD-labeled Jurkat T cells at specified time 
points following activation with both PMA and ionomycin.  Green fluorescence from YOPRO-1 indicates 
non-viable cells. 
 
Verification of IL-2R Labeling Using Flow Cytometry 
Flow cytometry analysis was then performed to corroborate these fluorescent imaging 
results, which suggest maximal IL-2R expression at approximately 48 hours following 
activation and a subsequent decrease in fluorescent intensity at longer activation times. 
Flow cytometry provides a convenient readout of cellular fluorescence in this assay, 
especially given the non-adherent nature of Jurkat T cell cultures. Correspondingly, cells 
were activated as before (with both PMA and ionomycin) and subsequently labeled for 
IL-2R expression at various time points using antibody-conjugated QDs. Representative 
flow cytometry histograms displaying differential IL-2R expression at 0, 48 and 84 hours 
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following activation are displayed in Figure 3.3. As in the fluorescent imaging 
experiments, minimal fluorescence is observed for unactivated cells (0 hr) owing to a 
lack of IL-2R expression in unactivated T cells. Fluorescent intensity has correspondingly 
increased for the entire cellular population following 48 hours of activation, indicating an 
overall increase in IL-2R production in this activated cell population. At longer activation 
times (84 Hr), the fluorescence due to IL-2R expression drops off dramatically for a 
significant fraction of this cell population, while a small number of cells remain 
fluorescent.  This decrease in fluorescent intensity is consistent with the expected wax 
and wane of IL-2R expression as the receptor is internalized upon engagement of 
secreted IL-2 for lysosomal degradation [112]. Additionally, this internalization of the 
IL-2•IL-2R complex acts in an autoregulatory manner to down-regulate further 
transcription of IL-2R, further decreasing receptor expression, and attenuating the T 
cell’s IL-2 responsiveness [122]. 
 
 
Figure 3.3  Flow cytometry analysis verifying selective QD labeling of IL-2R. Minimal background 
fluorescent intensity is observed for unactivated cells (top) compared to those cells activated for 48 hours 
(middle). The large increase in fluorescent intensity per cell is due to IL-2R expression. This fluorescence 
drops off by 84 hours (bottom) with a small population still exhibiting increased IL-2R expression. 
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Quantitative Determination of Cellular Activation Products 
Having demonstrated the specificity of these antibody-conjugated QDs for labeling 
IL-2R, quantification of specific cellular products was then performed to further evaluate 
the time course of T cell activation. Quantification of IL-2R expression was carried out 
utilizing fluorescence measurements on individual cells specifically labeled for IL-2R 
with QDs. Intensity measurements were made from fluorescent images using 
Metamorph® image analysis software. Briefly, circular regions containing individual cells 
were first identified in the bright field image as illustrated in Figure 3.4. These regions 
were then superimposed on the fluorescent image allowing readout of the integrated 
fluorescent intensity for each cell. Subsequent background subtraction and averaging 
over the entire population of cells for a given time point yielded the average fluorescent 
intensity per cell. The population of cells per time point varied between 50 and 200, due 
to differences in the number of viable cells in each image. Consequently, this 
fluorescence image analysis protocol provides a facile approach to rapidly assess IL-2R 
expression in activated populations of Jurkat T cells. 
 
 
Figure 3.4 Quantification of fluorescent intensity from microscopic images.  Metamorph® image analysis 
software was used to create circular regions containing individual, viable cells from a bright field image 
(left). This region mask was then superimposed onto the corresponding fluorescence image (right) to read 
out integrated fluorescent intensity per cell. 
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A graphical representation of IL-2R expression throughout the time course of T cell 
activation, as determined utilizing fluorescent image analysis, is presented in Figure 3.5 
(top panel). As anticipated, IL-2R expression peaks roughly 48 hours after activation, and 
is significantly diminished at longer activation times (but still above basal expression 
levels). Error bars at each time point in this graph represent one standard deviation of the 
mean. Additionally, since T cell activation is accompanied by the translation and 
secretion of IL-2, analysis of the supernatants at each time point utilizing an IL-2 ELISA 
provided verification of successful activation (Figure 3.5, bottom panel). Initial 
examination of the IL-2 ELISA data seemed to indicate a delayed response, as IL-2 
secretion is expected to coincide with IL-2R expression. However, since IL-2R acts to 
clear secreted IL-2 from the supernatant, accumulation of IL-2 in the supernatant is only 
observed after a significant portion of the expressed IL-2R has been internalized resulting 
in a sharp spike following the 48 hour time point. Thus, the IL-2 ELISA results confirm 
activation of the T cell populations by PMA and ionomycin. 
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Figure 3.5  Quantification of cellular activation products by fluorescence image analysis and ELISA.  
(Top) Specific labeling and QD fluorescence permits quantification of IL-2R expression at various time 
points following activation.  Average fluorescent intensity per cell was determined using Metamorph 
software and error bars represent one standard deviation of the mean.  (Bottom) Quantification of IL-2 
production by ELISA also provides verification of activation.  Initially, IL-2R acts to clear secreted IL-2 
from the supernatant, but a subsequent decreased expression of IL-2R allows for an eventual accumulation 
of IL-2 at later time points. 
 
Receptor Localization Subsequent to Quantum Dot Binding 
Confocal microscopy provided direct evidence of receptor internalization subsequent 
to expression and anti-IL2Rα-QD labeling (Figure 3.4). Cells that had been activated for 
72 hours were labeled as before with 10 nM anti-IL2Rα-conjugated QDs for 30 minutes. 
Following centrifugation, the labeled cells were resuspended in fresh media from which a 
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small population of cells were immediately fixed with 4% paraformaldehyde on poly-L-
lysine coated glass slides and mounted with Aqua PolyMount (Polysciences Inc.) for 
confocal microscopy. The remaining cells were allowed to remain in culture for an 
additional 24 hours before fixation and mounting. Confocal images of cells fixed 
immediately after labeling (Figure 3.4 A-B) show membrane associated extracellular 
labeling, while cells that have been allowed to remain in culture subsequent to labeling 
(Figure 3.4 B-C) demonstrate internalization of the QDs (Panels A and C are the center-
slices from the z-stack of confocal images, while panels B and D provide orthogonal 
views of the XZ and YZ planes). This indicates that the QD-receptor interaction is 
sufficiently strong as to undergo internalization, and that the relatively bulky QD probe 
does not prevent this internalization. 
 
 
Figure 3.6  Receptor localization subsequent to QD labeling.  Jurkat cells activated with PMA and 
ionomycin for 72 hours were labeled with anti-IL2Rα conjugated 655 QDs.  Cells were fixed immediately 
following QD labeling (A&B) and 24 hours after labeling (C&D).  Confocal images (A&C: center slice 
views; B&D: orthogonal views of the z-stack) indicate only membrane associated QDs for the cells fixed 
immediately following labeling.  Cells fixed 24 hours later, however, have clearly internalized at least a 
portion of the QD conjugates. 
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Summary and Future Directions 
Antibody-conjugated quantum dots (QDs) have been used to map the expression 
dynamics of the cytokine receptor IL-2Rα following Jurkat T cell activation. Controlled 
activation of populations of Jurkat T cells has been demonstrated and it is apparent that 
the dynamics of receptor expression can be monitored using antibody conjugated 
fluorescent QD probes. Maximal receptor expression was observed 48 hours after 
activation, followed by a sharp decrease consistent with IL-2R internalization subsequent 
to IL-2 engagement. Verification of T cell activation and specificity of QD labeling were 
demonstrated using fluorescence microscopy, ELISA and FACS analyses.  These 
antibody conjugates provide a versatile means to rapidly determine cell state and 
interrogate membrane associated proteins involved in cell signaling pathways.  
Ultimately, incorporation with a microfluidic platform capable of simultaneously 
monitoring several cell signaling pathways will aid in toxin detection and discrimination. 
This microfluidic platform capable of isolating and maintaining non-adherent cells, 
currently in development, will allow these time course studies to be performed in real 
time on thousands of individual cells in a massively parallel format.  Additionally, other 
signaling pathways can be simultaneously monitored in a similar manner by varying the 
emission wavelength of the QD probes and targeting these probes to other relevant 
membrane associated receptors. Future experiments will address simultaneous detection 
of multiple cell surface targets in order to more accurately portray the signaling state of 
the cell.  In addition, it may prove to be beneficial to compare the brightness of these QD 
conjugates to fluorophores traditionally used for low expression applications, although 
the improved sensitivity of QD probes has been demonstrated extensively.  Furthermore, 
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methods to use QDs intracellularly are being developed to obtain functional information 
of earlier events occurring within the signaling pathways that may be used in 
discrimination or prediction of cellular response to toxins. The effect of toxin exposure 
on expression dynamics will provide insights not only to the identity of the chemical or 
biological agent in question, but also provide valuable information on the method of 
pathogenesis as well as treatment. 
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CHAPTER IV 
 
 
SMALL MOLECULE APPROACH TO ELIMINATE SERUM PROTEIN 
ADSORPTION AT THE QUANTUM DOT SURFACE [123] 
 
 
Introduction 
Modifications of the quantum dot (QD) surface are routinely performed via covalent 
biomolecule attachment, and poly(ethylene glycol) (PEG) derivatization has previously 
been shown to limit nonspecific cellular interactions of QD probes. Attempts to 
functionalize ampiphilic QDs (AMP-QDs) with custom PEG derivatives having a 
hydrophobic terminus resulted in self-assembly of these PEG ligands to the AMP-QD 
surface in the absence of covalent coupling reagents. These self-assembled PEG-QDs 
exhibit improved passivation in biological environments, as demonstrated by 
electrophoretic characterization techniques, and are less susceptible to unwanted protein 
adsorption to the QD surface. Additionally, the artifactual fluorescent response protein 
adsorption can cause in biological assays is highlighted, and considerations for improved 
small molecule presentation to facilitate specific QD interactions are discussed. 
 
Background and Significance 
Quantum dots (QDs) were first reported as improved fluorophores for biological 
imaging applications in 1998 [2, 3], and have since seen increasing incorporation into 
numerous biological assays ranging from multiplexed fluorescent detection [67, 68] to 
tumor targeting in vivo [13, 72]. Their remarkable photostability has permitted biological 
processes to be observed on time scales unattainable with conventional organic 
fluorophores [29]. Their inorganic composition, which gives rise to these robust, size-
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dependent optical properties, is not conducive, however, to direct integration into 
biological assays. Surface modifications are initially required to permit dispersion in 
aqueous environments, and further functionalization is necessary to facilitate specific 
biological interactions. Initial attempts at water solubilization generally involved the 
displacement of organic capping ligands present on the quantum dot surface [2, 3, 61], 
but these approaches generally had a deleterious effect on the QD optical properties as 
well as reduced colloid stability. Retention of these organic capping ligands seemingly 
results in improved fluorophores; as such, encapsulation in phospholipids [18] or 
ampiphilic polymers [19, 20] has been widely used to confer water solubility. Biological 
specificity can subsequently be introduced through biomolecule attachment (refer to 
Chapter 1 for a comprehensive review). Consequently, the surface of a biologically active 
QD probe is surprisingly complex, with alternating regions of hydrophobicity and 
hydrophilicity, the possibility of a net positive or negative surface charge depending on 
functionalization, as well as the presence of numerous reactive chemical functionalities. 
A better understanding of this potentially reactive surface is required and will ultimately 
result in improved surface passivation and the elimination of undesirable biological 
interferences. 
 
Small Molecule Strategy for Labeling Membrane Associated Receptors 
A majority of fluorescent imaging applications involving QD probes utilize antibody 
conjugation to introduce biological specificity. The utility of biologically active small 
molecule QD conjugates for targeting membrane-associated receptors has been 
previously demonstrated [61, 62], and these small molecule conjugates have the potential 
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to provide several advantages over antibody recognition. Notably, the large size of 
antibodies (~150 kDa) adds significant steric bulk to an already sizable QD probe, 
whereas small molecule attachment provides minimal additional bulk. Despite the fact 
that antibodies can be designed to recognize virtually any biological target, the antibody-
antigen interaction varies dramatically from antibody to antibody, and the associated cost 
of antibody production significantly limits their utility. Small molecules, on the other 
hand, can have significantly reduced costs associated with synthesis, and the strength of 
the ligand-receptor interaction can be optimized through iterative ligand development. 
Additionally, a wide variety of cellular targets are available based on drug candidates 
from the known pharmocopia, and these improved probes would be of immediate benefit 
for various drug discovery applications. A small molecule QD targeting approach is 
schematically illustrated in Figure 4-1a. This ligand design incorporates a biologically 
active drug derivative (pink) on one end of a poly(ethylene glycol) (PEG) chain (blue). 
The PEG chain acts to reduce nonspecific interactions [23, 24, 124] as well as provide 
additional degrees of freedom for the drug derivative to interact with its cellular target. 
The terminus of the PEG chain is designed with a chemical functionality to facilitate 
attachment to the QD surface. Generally, a terminal amine is utilized in conjunction with 
standard carbodiimide coupling chemistry to covalently modify carboxylic acid 
derivatized AMP-QDs (ITK Qdots, Invitrogen Corp., formerly Quantum Dot Corp.). 
Alternately, a biotin can be introduced at this terminus to assemble ligands on 
commercially available streptavidin QDs, utilizing the extremely high affinity 
streptavidin-biotin interaction. Fluorescent imaging applications utilizing this small 
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molecule architecture have remained elusive, however, due to technical difficulties 
involving ligand design and associated ligand presentation on the QD surface. 
 
 
Figure 4-1:  Cartoon schematic illustrating (a) small molecule QD targeting approach, (b) potential 
interferences due to protein adsorption and (c) ineffective ligand presentation as a result of ligand 
interaction with the QD surface. 
 
It is apparent that ligand presentation on the QD surface must be optimized to 
facilitate specific binding of the small molecule-QD conjugate to a cellular target. 
Furthermore, nonspecific protein adsorption to the QD surface, specifically adsorption of 
the serum protein albumin, significantly inhibits the ability of a ligand to interact with a 
cellular target. Albumin, a 66 kDa serum protein present in standard blocking solutions 
and widely used in biological protocols, has previously been shown to complex to 
reactive QD surfaces and facilitate QD endocytosis [14]. This protein adsorption, or 
“biofouling” as it has been called, to the QD surface is less problematic in the case of the 
larger antibody (~150 kDa) or streptavidin (~50 kDa) QD conjugates, but it has a 
dramatic effect for the ligand-QD conjugates due to the added size and steric bulk of 
adsorbed protein (illustrated schematically in Figure 4-1b). PEG modification reportedly 
prevents serum protein adsorption [26], but in this chapter, continued protein adsorption 
despite PEG surface modification is demonstrated. Additionally, it is apparent that PEG 
derivatives with increasingly hydrophobic targeting functionalities have the ability to 
self-assemble to the surface of ampiphilic QDs in the absence of any added coupling 
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reagents (Figure 4-1c). This hydrophobic ligand self-assembly results in a passivated, 
nontargeted QD surface better suited to prevent nonspecific protein adsorption. In this 
chapter, electrophoretic characterization techniques useful for the identification of 
adsorbed proteins on the QD surface are discussed and the improved surface passivation 
resulting from the hydrophobic self-assembly of PEGylated ligands is demonstrated. 
Fluorescence microscopy further demonstrates the utility of these improved probes in 
reducing the QD background signal in vitro, and illustrates the artifact endosomal 
fluorescence staining which results from albumin adsorption. 
 
Results and Discussion 
 
Self-Assembly of Hydrophobic PEG derivatives to the Quantum Dot Surface 
Initial efforts were focused on the development of small molecule QD conjugates 
which would specifically interact with the serotonin transporter (SERT) membrane bound 
receptor. As such, custom ligands were synthesized to include a SERT selective terminus 
as well as a reactive amine terminus on either side of a PEG spacer. The amine 
functionality permitted covalent attachment to the carboxylic acid functionality on the 
surface of commercially available water-soluble ITK QDs, while the SERT selective 
small molecule would presumably be able to interact with its biological target. Agarose 
gel electrophoresis was used as verification of successful QD surface modification 
subsequent to covalent attachment of PEG ligands. As illustrated in Figure 4-2, the 
addition of PEG ligands acts both to decrease QD surface potential, by derivatizing 
negatively charged carboxylic acid residues, as well as increase the overall probe volume, 
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cumulatively resulting in a decreased electrophoretic mobility. Consequently, 
unconjugated QDs (lane 1) have an increased electrophoretic mobility in a 1% agarose 
gel as compared to IDT319 (lane 2) or IDT320 (lane 3) QD-conjugates. Unexpectedly, 
however, there was an observable difference between the relative mobility of IDT319 and 
IDT320 QD-conjugates. The only difference between these two ligands is a nine carbon 
alkyl linker between the PEG and the SERT-selective terminus, a seemingly negligible 
difference which should not result in any sizable disparity in electrophoretic mobilities, 
especially given the large overall molecular weight (~3400 Da) of the PEG ligand. This 
electrophoretic difference could therefore be attributed to differential ligand loading at 
the QD surface for these two similar ligands, perhaps mediated by added hydrophobicity 
at the IDT320 terminus. 
 
 
 
84 
 
Figure 4-2. Agarose gel electrophoresis demonstrating assembly of PEG derivatives to QD surface.  QD 
conjugates were run on a 1% agarose gel in TAE buffer for 80 min with a constant applied potential of 80 
V. Unconjugated AMP-QDs (Lane 1) have a characteristic electrophoretic mobility due to the deprotonated 
carboxylic acid residues on their surface.  Ligand conjugation to the QD surface retards the observed 
electrophoretic mobility, as seen for both IDT319 conjugates (Lane 2) and IDT320 conjugates (Lane 3).  A 
diminished electrophoretic mobility is also observed for these ligands without added EDC coupling 
reagent, indicative of self assembly to the QD surface.  Simply mixing IDT319 with QDs (Lane 4) results 
in conjugates which streak on the gel, indicating differential ligand loading; while IDT320 completely 
passivates the QD surface without covalent attachment (Lane 5).  Other ligands were assayed in an attempt 
to understand the chemical functionality required to drive surface modification.  PEG derivatives with 
either a short alkyl chain (IDT352, Lane 6) or an indole terminus (IDT353, Lane 7) both failed to drive 
surface modification in the absence of added coupling reagent.  Self assembly is driven by added 
hydrophobicity at the PEG terminus, as illustrated for both IDT361 (Lane 8) and IDT363 (Lane 9).  
Structures of various IDT compounds are illustrated on the right.  
 
To verify the possibility that a hydrophobic terminus could interact with the QD 
surface and cause self-assembly, the conjugation reaction was carried out without added 
EDC or NHS. EDC is a reagent that enables the formation of an amide bond between the 
terminal amine of the PEG ligand and carboxylic acid functionalities at the QD surface. 
Consequently, any observed surface modification in the absence of these coupling 
reagents would have to result from interactions with the ligand’s more hydrophobic 
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SERT-selective region. The absence of added coupling reagents, presumably resulting in 
no ligand attachment, should result in products with the same electrophoretic mobility of 
unconjugated AMP-QDs. However, it is apparent that QD surface modifications do occur 
in the absence of added coupling reagents, most notably for increasingly hydrophobic 
PEG ligands (lanes 4-9, Figure 4-2). QDs mixed with IDT319 only resulted in partial 
surface modification (lane 4), suggesting that ligand attachment is at least partially 
dependent upon amide bond formation. The streaking observed in the IDT319 QD 
product in the absence of EDC and NHS is indicative of differential ligand loading at the 
QD surface. The IDT320 QD product (lane 5), however, results in complete surface 
modification and faithfully reproduces the electrophoretic mobility observed when the 
conjugation was carried out in the presence of EDC and NHS (lane 3). This indicates that 
IDT320 assembles independent of covalent ligand attachment and acts to passivate the 
reactive AMP-QD surface. 
Additionally, alternate PEG ligands were synthesized to further elucidate the 
chemical functionality required to drive the self-assembly of PEG ligands to the AMP-
QD surface in the absence of coupling reagents. PEG ligands terminated with either a 
seven-carbon alkyl chain (IDT352, lane 6) or an indole ring (IDT353, lane 7) did not 
result in appreciable QD surface modification. A PEG derivative with a longer twelve-
carbon alkyl chain (IDT363, lane 9), however, did result in ligand assembly to the QD 
surface, as illustrated by a characteristic retardation of electrophoretic mobility. Taken 
together, these data indicate that this self-assembly of PEG ligands to the QD surface is 
driven by hydrophobic/hydrophilic interactions, and not a result of a specific chemical 
functionality present in the SERT-selective termini. Additionally, an alternate SERT-
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selective cyano derivative (IDT361, lane 8), with a chemical functionality similar to 
IDT320 but synthesized via different intermediates, results in self-assembly to the QD 
surface; this further corroborates the importance of added hydrophobicity for driving 
assembly of PEG ligands to the QD surface. 
 
Verification of Ligand Assembly by 1H NMR 
While agarose gel electrophoresis characterization qualitatively indicate the self-
assembly of hydrophobic PEG derivatives to the QD surface, additional spectroscopic 
proof of this interaction is certainly necessary for verification of any such claims. As a 
result, a NMR experiment was devised to provide spectroscopic characterization of these 
QD-ligand structures and help quantify ligand coverage to verify any conclusions drawn 
from electrophoretic mobility measurements. Given the large number of structurally 
equivalent hydrogen atoms in their long PEG chains, the 1H NMR spectra of IDT319 and 
IDT320 predominately consist of a single large peak around 3.64 ppm (Experimental 
Methods, Chapter 2). The 1H spectrum of unconjugated AMP-QDs (also Chapter 2) has 
no such feature present at that chemical shift, indicating the utility of this spectral feature 
in assessing ligand conjugation to the QD surface. NMR samples were diluted into 
deuterium oxide following QD conjugation to either IDT319 or IDT320, carried out as 
before both with and without added EDC coupling reagents, and special care was taken to 
eliminate any unbound ligand following conjugation (see Chapter 2). The 1H NMR 
spectra of IDT319 and IDT320 conjugates, presented in Figure 4-3, illustrate IDT320 
conjugation to the QD regardless of any coupling reagents, an indication that the 
observed differences in electrophoretic mobilities result directly from PEG surface 
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modifications. A large PEG peak is apparent for both the IDT319 and IDT320 QD-
conjugates synthesized in the presence of EDC coupling reagents (Figure 4-3A). While 
this peak remains for IDT320 conjugates synthesized in the absence of any added 
coupling reagents, a demonstration that these hydrophobic PEG derivatives self-assemble 
to the QD surface, the IDT319 peak is significantly diminished in the absence of EDC 
(Figure 4-3B). The presence of additional peaks from the AMP-QD, presumably due to 
protons present in its ampiphilic polymer coating, permit normalization of integral areas 
with respect to QD concentration and facilitate straightforward sample-to-sample 
comparisons for determination of relative ligand loading. As expected, the integral areas 
for these QD-conjugates, each normalized to a doublet of doublets at 3.47 ppm from the 
AMP-QD, clearly indicate a similar ligand loading for IDT320 regardless of coupling 
reagents, while the IDT319 conjugates have approximately a 4-fold decrease in ligand 
loading without covalent attachment (Figure   4-3, inset). These results are obviously 
consistent with the results of the agarose electrophoresis experiment, in which any added 
ligand loading results in a diminished electrophoretic mobility. Taken together, these data 
provide an unambiguous demonstration of the attachment of PEG derivatives to the QD 
surface and provide an additional means to determine and compare ligand loading. 
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Figure 4-3.  1H NMR characterization of QD-ligand conjugates.  QD conjugation reactions to either 
IDT319 or IDT320 were carried out (A) with the addition of EDC coupling reagents or (B) in the absence 
of any coupling reagents; conjugates were then purified of any unbound ligand before analysis.  
Consequently, the presence of a peak at 3.64 ppm in the 1H NMR spectra, due to the long PEG chain 
present in each ligand, is indicative of ligand attachment to the QD surface.  (A) In the presence of EDC 
coupling reagents both IDT320 (upper spectrum) and IDT319 (lower spectrum) present a spectral feature 
indicating ligand attachment.  (B) Without added coupling reagents, the feature is still clearly present for 
the IDT320 conjugates (upper spectrum), while this peak is greatly diminished for IDT319 conjugates 
(lower spectrum).  The integral area of each PEG peak, which is directly proportional to amount of ligand 
present, is therefore indicative of ligand loading, but all areas must be first be normalized to a QD feature to 
permit any sample-to-sample comparison.  (Inset) Quantification of integral areas, each normalized to the 
AMP-QD doublet of doublets at 3.5 ppm, clearly demonstrate equivalent ligand loading for IDT320 
conjugates regardless of added coupling reagents, while the IDT319 conjugates demonstrate a roughly 4-
fold decrease in ligand attachment in the absence of coupling reagents. 
 
Artifact Fluorescent Staining in Cellular Assays Resulting from Albumin Adsorption 
The utility of this surface modification approach, and the improved QD surface 
passivation, could be of great importance to biological imaging applications. Significant 
research efforts have been focused toward the development of small molecule conjugated 
QDs for biological imaging application, and these custom PEG ligands should ultimately 
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facilitate specific QD recognition of SERT. An initial attempt to demonstrate specific 
targeting of SERT in a cellular assay using these custom PEG derivatives, however, 
produced intriguing results. For this assay, SERT-expressing LLC-PK1 cells were 
incubated with either IDT319 or IDT320 ligand-conjugated QDs in a bovine serum 
albumin (BSA) blocking solution for 30 min at 37 °C, rinsed three times with cold PBS, 
and immediately imaged with a fluorescent microscope at 100× magnification. The 
observed fluorescent staining pattern for IDT319 QD conjugates (Figure 4-4A) was 
dramatically different from the negligible fluorescent staining observed for IDT320 
conjugates (Figure 4-4B). This staining pattern observed for the IDT319 conjugates was 
not uniform across the field of view, but isolated to individual cells, an indication of 
specificity and apparently not the result of nonspecific QD interactions with the cellular 
membrane. This labeling, however, could not be blocked with the selective serotonin 
reuptake inhibitor paroxetine, and was apparent in parental cell lines which do not 
express SERT (data not shown), a clear demonstration that the custom PEG ligands were 
not mediating specific labeling of SERT. Additional imaging experiments indicated that 
the observed QD staining pattern involved active intracellular transport, demonstrated a 
cell cycle dependence, and could not be blocked with free ligand (Figure 4-5). It became 
apparent that albumin was mediating this effect when AMP-QDs, without any added 
surface modification, recapitulated the same fluorescent staining pattern following an 
initial incubation in a solution containing BSA (Figure 4-4C). Taken together, these data 
indicate that BSA adsorption (illustrated schematically in Figure 4-4) to AMP-QDs and 
IDT319 QD conjugates result in an endosomally associated fluorescent staining pattern, 
90 
while improved surface passivation of IDT320 QD conjugates prevent protein adsorption 
and any associated artifactual cellular labeling. 
 
Figure 4-4.  Cellular imaging with IDT319 and IDT320 QD conjugates. SERT-expressing LLC-PK1 cells 
were incubated with various QD conjugates in the presence of BSA, a standard blocking agent. QD 
fluorescence micrographs (top) and corresponding bright field composite overlay images (bottom) are 
shown for IDT319 QD-conjugates (A), IDT320 QD-conjugates (B), and unconjugated AMP-QDs (C).  The 
fluorescent staining observed for the IDT319 conjugates is not ligand mediated, since the same pattern is 
observed with unconjugated AMP-QDs; rather this artifactual staining is apparently the result of albumin 
adsorption (illustrated schematically at left).  No such albumin associated artifactual staining is observed 
for IDT320 QD conjugates, owing to the improved passivation of the IDT320 QD surface. 
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Figure 4-5.  Characterizing the cellular response of IDT319 QD conjugates in the presence of serum 
proteins.  Cellular labeling conditions were varied in order to better understand the nature of the observed 
artifactual labeling with IDT319 QD in a high serum protein blocking solution (2% BSA with 10% horse 
serum).  Cells initially serum deprived overnight prior to QD labeling demonstrated a significant increase 
in QD fluorescence (Left, Serum Deprived)), an indication that this artifactual response is cell cycle 
dependent.  This cell cycle dependence also explains the non-uniform nature of fluorescent staining for 
protein-QD conjugates in the absence of serum deprivation.  Fluorescent staining caused by serum protein 
adsorption also exhibits a distinct temperature dependence.  A non-uniform, endosomal fluorescent staining 
pattern is observed when the QD labeling is carried out at room temperature (Middle, 25 oC) while all 
fluorescent labeling is blocked upon QD incubation at 4 oC (Right).  This temperature dependence suggests 
active cellular transport is involved in the observed fluorescent labeling, consistent with endosomal 
association. 
 
Verification of Albumin Adsorption to Quantum Dot Surface 
QD-BSA conjugates are reportedly photostable Endosomal markers [14], but it was 
assumed that PEG surface modification would passivate the reactive QD surface and 
eliminate any undesirable protein associations. A prior investigation has highlighted the 
utility of PEG to significantly reduce nonspecific interactions of AMP-QDs in live cell 
assays [24], but these previous results were collected in the absence of serum protein 
blocking conditions, and any potential protein interference was consequently not 
explored. It is now apparent that nontargeted PEG-QDs result in an endosomal 
fluorescent staining pattern for cellular assays where serum protein blocking conditions 
are employed (Figure 4-6). These cellular imaging results seem to indicate that BSA 
adsorption occurs despite PEG modification; yet, this protein adsorption to the QD 
92 
surface must first be verified in order to validate these assumptions. Gel-filtration 
chromatography has previously been employed as an analytical tool to assess serum 
protein interactions with QD surfaces [26], and has proven useful in identifying 
electrostatic interactions as the most likely cause of serum protein adsorption to QD 
surfaces [125]. An alternate approach using polyacrylamide gel electrophoresis (PAGE) 
to assess protein-QD interactions is described herein, without the added expense of gel-
filtration chromatography instrumentation. Previous work has identified the utility of 
PAGE for characterization of QDs covalently modified with BSA [126, 127], but these 
studies focused on denaturing SDS-PAGE given the covalent nature of the QD surface 
modification. A nondenaturing, native gel was chosen for our assay in order to maintain 
the interaction which causes albumin adsorption to reactive QD surfaces. This approach 
initially facilitates electrophoretic separation of QDs from unconjugated protein, owing to 
a significant size difference; additionally, the resulting resolved gel can subsequently be 
stained to assess protein localization. Colocalization of a protein band, visualized via 
colorimetric detection, with the QD band, as determined by fluorescence, is therefore 
indicative of a protein-QD interaction; conversely, complete separation of protein from 
QDs occurs in the absence of any protein-QD interaction. 
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Figure 4-6.  Demonstrating a similar artifactual response for other PEGylated QDs. Red emitting AMP-
QDs (655 nm emission), covalently modified with PEG2000 as previously reported [24], result in the same 
non-uniform fluorescent staining pattern as IDT319 derivatized PEG conjugates upon cellular incubation in 
serum blocking conditions.  This artifactual fluorescent staining is observed despite the improved 
passivation of PEGylated QD conjugates. 
 
Protein analysis is routinely performed using PAGE and frequently incorporates both 
a lower percentage polyacrylamide stacking gel with a higher percentage resolving gel. 
The QD characterization technique developed in this study makes use of a 2.5% 
polyacrylamide stacking gel and a 10% resolving gel. As large particles experience a 
decreased electrophoretic mobility with increasing polyacrylamide concentration, the 
initial 2.5% gel facilitates QD migration and protein separation, while the 10% resolving 
gel acts a barrier to the QDs, concentrating them to an individual band (Figure 4-7, left). 
A Coomassie Blue stain after electrophoretic separation subsequently permits 
colorimetric determination of protein localization (Figure 4-7, right). Using this 
approach, free BSA separates into three distinct bands, characteristic of albumin 
monomers, dimers, and globulins (Figure 4-7, lane 1), but BSA adsorbed to the QD 
surface appear as an additional band coincidental with the QD fluorescence (highlighted 
with red box). Of particular notice, the dark band associated with AMP-QDs (lane 6) 
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indicates a large degree of albumin association. Additionally, IDT319 conjugates (lane 4) 
have an increased albumin adsorption as compared to their IDT320 counterparts (lane 2), 
consistent with the cellular imaging observations. The covalent PEG attachment for the 
IDT319 conjugates does act to reduce the amount of albumin adsorption as compared to 
AMP-QDs, but apparently this minimal amount of protein is still sufficient to cause the 
observed artifact in fluorescent imaging experiments. Control samples consisting of QD 
conjugates without added BSA (lanes 3, 5, and 7) provide verification that the observed 
staining is not due to QD interferences. While this PAGE characterization may lack the 
sensitivity of a comparable gel-filtration approach, it does serve as a facile tool to quickly 
assess potential protein interactions at the QD surface without any significant 
instrumentation expenditure. 
 
 
Figure 4-7.  Polyacrylamide gel electrophoretic determination of albumin adsorption to reactive QD 
surfaces.  A fluorescent image (left) illustrates QD accumulation at the interface between the 2.5% stacking 
gel and the 10% resolving gel.  A bright field image following Commassie Blue staining (right) confirms 
protein localization.  Unassociated BSA is evident in the resolving gel as three characteristic bands.  
Albumin adsorbed to the QD surface, however, colocalizes with the QD fluorescent bands (highlighted 
with a red box).  Lane 1: BSA without any QDs. Lane 2: IDT320 QDs with BSA. Lane 3: IDT320 QDs, no 
BSA.  Lane 4: IDT319 QDs with BSA. Lane 3: IDT319 QDs, no BSA. Lane 6: AMP-QDs with BSA. Lane 
7: AMP-QDs, no BSA.  The passivated IDT320 QD show minimal albumin adsorption (Lane 2) compared 
to IDT319 conjugates (Lane 4), while AMP-QDs show the highest degree of albumin association (Lane 6). 
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Summary and Future Directions 
It is now apparent that increasingly hydrophobic ligands will self-assemble to the QD 
surface, presumably through an interaction with the hydrophobic organic capping ligands 
present on the QD surface. The development of a small molecule approach to specifically 
target membrane associated receptors with QDs is obviously dependent upon ligand 
presentation at the QD surface. Unfortunately, with regards to small molecule targeting, 
these hydrophobic termini are not able to interact with their intended targets due to this 
intimate association with the QD surface. An improved architecture for optimal ligand 
presentation on the surface of AMP-QDs must therefore incorporate a less hydrophobic 
targeting compound, limiting the potential interaction the drug derivative will have with 
the QD surface. Previous small molecule GABAc receptor specific muscimol-QD 
derivatives [62] incorporate a more hydrophilic targeting functionality which is 
deprotonated at physiological pH, thus permitting covalent attachment to the QD surface 
without adversely affecting ligand presentation. It is apparent, however, that certain 
biological targets will necessarily require hydrophobic compounds for effective labeling. 
In these instances, one possible QD targeting strategy would utilize a two step labeling 
approach incorporating biotinylated ligands to initially facilitate a specific interaction 
with an intended biological target and subsequently be recognized by a streptavidin 
conjugated QD.  This method will allow the hydrophobic targeting terminus to seek out 
its intended target in the absence of QDs, altogether eliminating the necessity of ligand 
presentation at the QD surface [128]. Alternately, effective presentation of hydrophobic 
drug derivatives on the AMP-QD surface could be accomplished through the use of a 
rigid linker, such as an oligoproline for example, in the place of a PEG chain. This added 
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rigidity would conceivably prevent the ligand from being able to wrap back on itself and 
limit the potential interaction it might have with the QD surface. Furthermore, recent 
advances in developing water soluble QD conjugates via the displacement of organic 
capping ligands, thus eliminating significant regions of hydrophobicity, may ultimately 
provide a suitable platform for hydrophobic ligand presentation, but issues regarding 
diminished colloidal stability and fluorescence quenching are still of concern for these 
novel conjugates [129, 130].  In addition to these observations regarding ligand 
presentation, we have demonstrated the improved passivation resulting from self 
assembly of PEG derivatives, which have proven to be even less reactive than covalently 
modified PEG-QDs. These self assembled conjugates may ultimately provide a useful 
platform for biological applications owing to their ability to eliminate unwanted protein 
adsorption and other associated interferences. 
Previous reports have focused on identifying appropriate blocking strategies and 
surface modifications which limit biological recognition of nanoparticles and reduce their 
nonspecific binding to cellular membranes. The data presented in this chapter, however, 
highlight a seemingly subtle difference; certain biological compounds can inadvertently 
alter the QD surface, resulting in an altogether different type of artifactual labeling. These 
data highlight the potential interference protein adsorption can cause in cellular assays 
which incorporate QD probes, despite efforts to limit QD reactivity through PEG surface 
modification, and it is immediately apparent that the observed endosomal staining could 
easily be mistaken for a specific interaction. These results could provide insight into 
several seemingly anomalous QD labeling patterns reported throughout the scientific 
literature. Serum protein adsorption, and in particular albumin adsorption, is likely to 
97 
occur in any in vivo analysis and is also likely to occur in numerous in vitro assays, where 
serum blocking is widely employed to limit unwanted fluorescent background staining. 
While the use of serum proteins is generally accepted in biological protocols, and 
furthermore necessary for maintaining long term cellular viability, their potential 
reactivity with QD probes is frequently neglected. At least one study has demonstrated 
the importance of selecting an appropriate blocking solution for effective and specific QD 
labeling [25], and these results provide further insight into the persistent nature of this 
problematic interference. Conversely, an alternate report has highlighted a potential 
application utilizing protein adsorption on gold nanoparticles to facilitate intracellular 
delivery and mediate materials transfection [131], consistent with the intracellular 
staining observed with our own albumin-modified QDs. Consequently, protein adsorption 
can be either desirable or an unwanted interference depending on the nature of the 
biological assay in question, which further highlights the importance of improved 
approaches to control the QD surface and mediate biomolecule attachment. 
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CHAPTER V 
 
 
SPECIFIC LABELING OF THE SEROTONIN TRANSPORTER WITH 
SMALL MOLECULE QUANTUM DOT CONJUGATES 
 
 
Introduction 
A family of Na+- and Cl--coupled neurotransmitter transporter proteins has long been 
known to play a critical role in regulating extracellular monoamine concentrations and 
terminating synaptic transmission. These substrate-specific membrane transporters, 
including the transporters for serotonin (SERT), dopamine (DAT), norepinephrine 
(NET), γ-aminobutyric acid, glycine, and proline (among others) [132], all share a 
distinct structural homology, each consisting of 12 transmembrane domains with 
intracellular C- and N-termini [133]. These transporters represent established targets for 
numerous psychostimulants and antidepressants, which exert their psychotropic effect 
through the inhibition of transporter function to cause elevated extracellular monoamine 
concentrations. Furthermore, several neurotoxins have been identified which utilize 
transporters to gain intracellular delivery and induce a cytotoxic effect [134], and genetic 
mutations affecting transporter expression and activity have been implicated in various 
disease states [135]. Analytical approaches to investigate fundamental transporter 
processes such as their expression, function, and localization have largely relied on 
autoradiographic methodologies incorporating radiolabeled substrates. These techniques, 
however, are limited due to poor spatial and temporal resolution, and are additionally 
cumbersome due to specialized training and licensing required for the handling and 
disposal of radioactive compounds. The research presented in this chapter highlights 
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recent progress in the development of small molecule QD conjugates to specifically 
interrogate SERT expression in living cells. 
 
Pharmacological Significance of the Serotonin Transporter 
Cell surface receptors, ion channels, and transporters are critical components of 
signaling and excitability within the nervous system. As such, they represent the majority 
of drug targets currently being explored in the pharmaceutical industry. Serotonin, in 
particular, is a critical neurotransmitter in brain circuits subserving mood, emotion, 
appetite, social behavior and libido. Whereas serotonin levels in the presynaptic neuron 
are established by biosynthetic and degradative pathways, the synaptic actions of 
serotonin at serotonin receptors are principally constrained by rapid clearance sustained 
by the serotonin transporter (SERT). SERT is the principle site of action for selective 
serotonin reuptake inhibitor (SSRI) antidepressants and has been an established drug 
target for decades [136, 137] (e.g. Prozac, Paxil, Zoloft, Desiril and Elavil are all SSRIs). 
In fact, by the year 2000, annual U.S. sales of SSRI antidepressants totaled approximately 
seven billion dollars [138].  Only recently, however, has it been shown that transporter-
mediated clearance of neurotransmitters is under tight regulation including polarized 
expression of transporter proteins [139], protein kinase-mediated alterations in cell 
surface expression [140], and activity-dependent phosphorylation and redistribution 
[141]. Consequently, many drugs appear to alter the responsiveness, distribution and/or 
surface abundance of their protein targets following chronic occupancy. Additionally, the 
SERT gene exhibits polymorphisms that alter expression and activity which have been 
correlated with disease states such as autism, obsessive compulsive disorder (OCD), 
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depression, and anxiety [135, 142]. Advances in understanding the basic mechanisms 
underlying these patterns of localization, ligand-dependent redistribution, and correlation 
with specific disease states require tools sufficient to localize transporter proteins in situ 
in living cells. 
 
Small Molecule Quantum Dot Conjugates to Interrogate SERT 
Small molecule QD conjugates capable of interacting with SERT were initially 
prepared to circumvent the numerous disadvantages associated with various isotopic 
approaches [61]. Prior to this proof-of-concept demonstration, fluorescent imaging of 
SERT has been limited to immunofluorescent (IF) staining on fixed and permeablized 
cell cultures, where selectivity was introduced with an antibody specific to the 
intracellular N- or C- terminal domains of SERT [143, 144]. While antibodies specific to 
an extracellular epitope of SERT have been developed [145, 146], no fluorescent imaging 
employing an extracellular antibody has been demonstrated to date for live cell cultures. 
These extracellular antibodies have instead proven useful for both western blot analyses 
and immunoprecipitation assays, but they apparently lack a sufficiently strong interaction 
to facilitate IF staining. The SERT-selective, small molecule QD conjugates have 
therefore provided the only demonstration of fluorescent labeling of SERT in a live cell 
assay [61]. These QD conjugates, however, had associated drawbacks which ultimately 
limited their utility in expanded biological applications.  Most notably, the QDs 
employed in this study had a reduced colloidal stability as well as a diminished quantum 
yield, an unintended consequence of the ligand exchange reaction used to derivitize the 
QD surface.  Improved fluorescence and solution stability was eventually afforded, 
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through a collaboration with the Quantum Dot Corporation, by encapsulating QDs in an 
ampiphilic polymer (AMP-QDs) [19], and all subsequent research efforts were then 
focused on modifying this AMP-QD scaffold to generate improved small molecule QD 
conjugates. 
Despite their improved optical properties and enhanced solution stability of these 
AMP-QDs, numerous technical difficulties had to be overcome prior to their routine 
incorporation in biological assays using a small molecule targeting strategy. Notably, 
AMP-QDs exhibited a large degree of nonspecific interactions in cellular assays, and it 
was demonstrated that surface modifications with PEG could be employed to limit these 
undesirable interactions [24]. Having detailed an approach which greatly reduced the 
observed nonspecific cellular interactions without adversely affecting the QD’s 
photophysical properties, significant research efforts were then directed at modifying the 
PEG chain to facilitate specific interactions with cellular membrane receptors.  
Consequently, the introduction of biological specificity has relied on a PEG backbone to 
both eliminate nonspecific cellular interactions and additionally provide a scaffold which 
extends a small molecule drug derivative away from the QD surface to facilitate small 
molecule recognition of a biological target.  A universal approach was therefore 
developed to derivatize PEG linkers to include one receptor specific terminus and an 
opposing reactive amine terminus, permitting subsequent covalent attachment to AMP-
QDs [124].  Consequently, high affinity ligands for both the dopamine transporter (DAT) 
and the serotonin transporter (SERT) have been developed and been shown to retain 
biological activity, via a competitive binding assay, even after conjugation to the QD 
surface [147, 148].  Despite the development of biologically active small molecule-QD 
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conjugates, specific cellular recognition and labeling was not immediately forthcoming as 
additional interferences further complicated fluorescent imaging applications.   
Finally, two additional interferences became evident after continued attempts to 
demonstrate specific labeling of cellular targets with these biologically active QD 
conjugates, namely: (1) ineffective ligand presentation at the QD surface and (2) protein 
adsorption to the QD surface. As described in Chapter IV, small molecule drug 
derivatives which are employed to specifically interact with a biological target can self-
assemble to the AMP-QD surface due to hydrophobic interactions [149].  Consequently, 
the hydrophobicity or hydrophilicity of the drug derivative targeting compounds is a key 
determinant in the efficacy of ligand presentation at the QD surface.  While relatively 
hydrophilic ligands can be covalently attached to AMP-QDs surface and still be useful 
for fluorescent imaging applications, as is the case for effective small molecule-QD 
conjugate recognition of GABAc receptors [62], increasingly hydrophobic derivatives 
will have a strong interaction with the QD surface and not be available to interact with 
their intended biological target. Additionally, the presence of serum proteins in biological 
labeling protocols can result in another potential interference which can further 
complicate fluorescent imaging applications. While PEG modification undoubtedly 
reduces nonspecific interactions in cellular assays [24], we have demonstrated albumin 
adsorption to the QD surface will occur despite PEG attachment and result in artifactual 
fluorescent staining [149].  Care must therefore be taken to avoid or eliminate all 
potential interferences in designing an effective small molecule QD labeling protocol to 
specifically interrogate a biological target. 
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Successful Small Molecule Quantum Dot Labeling in Xenopus Laevis 
Building on the successful demonstration of GABAc labeling with muscimol-
conjugated QDs [62], the Xenopus oocyte model system was subsequently employed to 
demonstrate specific targeting of membrane bound SERT proteins. Isolated from the 
ovarian lobes of gravid adult female Xenopus laevis toads, Xenopus oocytes are easily 
transfected by means of cRNA microinjection, and have been widely used for studies 
involving membrane bound receptor expression. As such, these oocytes have evolved 
into a robust model system for QD labeling studies which provide intrinsically low 
nonspecific QD interactions. Initial investigations with SERT-expressing Xenopus 
oocytes identified IDT318 as a suitable ligand for specific labeling of SERT with QDs.  
IDT318 (Figure 5-1) consists of a SERT selective drug derivative attached to a 
biotinylated PEG-5000 via a long chain (11-carbon) alkyl spacer.  
 
 
Figure 5-1. Structure of the SERT-selective ligand IDT318. This ligand incorporates a biotin terminus 
(left) to permit recognition by streptavidin-QDs, a long PEG chain with a long chain alkyl spacer (middle) 
and a SERT-selective drug derivative to facilitate specific recognition of SERT (right). 
 
The added hydrophobicity of the long alkyl chain is apparently required for SERT 
recognition, which precludes its direct attachment to the QD surface due to ineffective 
ligand presentation as a result of hydrophobic interactions with the QD surface. The 
biotin terminus, however, permits a two step labeling protocol to be employed, taking 
advantage of the high affinity biotin/streptavidin interaction. In this protocol, IDT318 is 
first allowed to interact with SERT-expressing oocytes in the absence of QDs, 
eliminating any potential interaction the hydrophobic ligand may have with the QD 
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surface.  Excess unbound ligand is then washed away and streptavidin-QDs (SA-QDs) 
can then be used to detect the biotin terminus of the ligand, ultimately facilitating specific 
QD labeling. While SERT expression in an oocyte model provides a useful platform for 
ligand screening, optimization in a mammalian cell model is ultimately required to 
realize the full potential of these unique QD conjugates in applications ranging from the 
elucidation of cellular signaling pathways, to high-throughput drug discovery and 
eventually to their administration in vivo. 
 
Suspension Cells Result in Diminished Fluorescent Background 
Having developed a better appreciation for the potential interferences that can 
adversely affect small molecule-QD conjugate recognition of biological targets, a 
modified protocol was subsequently developed in an attempt to demonstrate specific 
labeling of SERT expressed in a mammalian cell line using IDT318.  As a control 
experiment for this two-step labeling method, adherent mammalian cells were incubated 
simply in a solution of SA-QDs in KRH buffer, without added serum proteins for 
blocking purposes, and an extremely high background fluorescence was observed with 
especially significant QD association to the glass slide (illustrated in Figure 1A).  While a 
blocking solution would reduce this background, it would potentially interfere with small 
molecule recognition and QD labeling.  Furthermore, extensive rinsing following QD 
labeling only marginally reduced the observed background and frequently caused the 
cells to lift from the plate altogether.  Previous work, however, with Jurkat cells [40] as 
well as primary lymphocytes (Figure 1B), which are both suspension cell lines, indicated 
no significant QD background upon incubation with similar SA-QD solutions.  This 
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reduced fluorescent background can be attributed to improved rinsing by centrifugation 
to rinse away unbound QDs and eliminating potential nonspecific QD interactions with 
the culture vessel.  This exceedingly low background suggests that a suspension cell 
model would be an improved mammalian cell platform for QD detection. 
 
 
Figure 5-2.  Nonspecific fluorescent background from 5 nM SA-QD exposure to adherent LLC-PK1 (A.) 
or primary lymphocyte suspension cells (B.)  Fluorescent micrographs (top) with corresponding DIC 
overlay images (bottom) illustrate a high degree of nonspecific SA-QD interaction to the adherent cell 
culture, most notably to the regions where the glass slide is exposed.  A significant reduction in fluorescent 
background is seen for suspension cells, causing a dramatic increase in the sensitivity of QD detection. 
 
Results and Discussion 
 
Identifying a Suitable Suspension Cell Line for SERT Expression 
In order to take advantage of the extremely low fluorescent background afforded by 
suspension cells, it was initially necessary to identify a suitable non-adherent cell line to 
assay the expression of SERT.  Previous reports have indicated that peripheral blood 
lymphocytes endogenously express functional SERT [150], but initial efforts to detect 
SERT in these cells were unsuccessful (apparently due to low expression levels).  
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Additional efforts to transiently transfect Jurkat cells to express SERT also failed; as 
suspension cell lines are notoriously difficult to transfect with cationic lipid or liposome 
transfection reagents [151].  A transient transfection approach was then employed to 
drive SERT expression in adherent HEK-293T cells, with the intention of generating a 
cellular model system with an elevated expression of SERT.  These SERT expressing 
cells could then be lifted from the culture vessel, labeled with QDs in suspension, and 
subsequently assayed as suspension cells.  While stable cell lines known to express SERT 
are available, this transient transfection of plasmid cDNA seemed to provide an added 
level of control over cellular expression levels. Stable lines gradually loose functional 
expression of transfected proteins with increasing cell passage number, while transient 
transfection can routinely provide a distinct population of cells with elevated SERT 
expression just 48 hours after transfection. Sham-transfected cells (Ø-293T) can also be 
generated by performing the transfection with empty pcDNA3.0 vector, resulting in a 
suitable negative control cell population which lack SERT expression. 
Successful transfection, resulting in functional SERT expression, was subsequently 
verified with IDT307, a small molecule which is selectively transported by monoamine 
transporters and results in a distinct intracellular fluorescence [152]. This compound has 
therefore provided a rapid and facile approach to confirm the expression of SERT, 
altogether eliminating a great deal of uncertainty regarding receptor expression (cellular 
imaging with IDT307 is discussed in greater detail in Appendix A). Prior to the 
development of IDT307, verification of SERT expression could only be performed via 
isotopic uptake analyses, which were performed sparingly due to the experimental 
difficulty associated with this approach. IDT307, on the other hand, can be used to 
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demonstrate successful transfections by a simple fluorescent assay. Incubating cells with 
IDT307 results in a distinct intracellular green fluorescence for SERT-expressing 
populations (Figure 5-3A), while no such fluorescence staining is observed for cells 
lacking SERT expression (Figure 5-3B). IDT307 was therefore utilized in subsequent 
analyses as a means to initially confirm SERT expression, eliminating the expenditure of 
time and reagents in the instances where SERT is not functionally expressed. 
 
 
Figure 5-3. Demonstrating SERT expression with IDT307. Successful transfection was verified by 
incubating both SERT-transfected (A) and sham-transfected (B) cells with 5 μM IDT307. SERT expression 
is confirmed by a characteristic intracellular green fluorescence. 
 
Successful Labeling of SERT in HEK-293T Cells with IDT318 
This ability to verify SERT expression prior to QD labeling experiments, combined 
with the identification of previously mentioned interferences, ultimately allowed for the 
development of a protocol to successfully label SERT in mammalian cell cultures. This 
labeling protocol was derived from successful QD labeling experiments in an oocyte 
model system, and consequently utilized a two-step labeling with IDT318 and 
streptavidin-QDs to fluorescently interrogate SERT expression.  Transiently transfected 
HEK-293T cells were therefore incubated with a 1 μM solution of IDT318 in PBS for 
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one hour, optimized parameters from experiments with oocytes, before dissolution from 
the plate using a trypsin-EDTA solution and subsequent QD labeling in suspension. The 
two-step labeling eliminated any ligand interactions with the QD surface, and 
interferences due to albumin adsorption were avoided by removing serum protein 
blocking. Specific labeling of SERT is evident for SERT-expressing HEK293T cells 
(Figure 5-4A), which can be blocked with the SSRI paroxetine (Figure 5-4B) and is not 
apparent in sham-transfected cells lacking SERT (Figure 5-4C).  
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Figure 5-4. SERT specific labeling in mammalian cells with IDT318.  Adherent HEK-293T cells were 
transiently transfected with plasmid DNA to drive SERT expression (A and B) or empty pcDNA3.0 vector 
(C, negative control).  These cells were initially exposed to 1 μM IDT318 biotinylated ligand in PBS, then 
lifted from the plate and labeled in suspension with 2.5 nM streptavidin-QDs.  Increased fluorescent 
intensity is apparent for SERT-expressing cells (A).  Pre-incubation with 20 μM paroxetine (a SSRI) 
reduces the fluorescent labeling in SERT-expressing cells (B) to levels comparable to sham-transfected 
cells which lack SERT (C).  Images were acquired at 20× (top) or 100× (bottom) magnification and have 
been thresholded equivalently for clear comparison. 
 
Fluorescent microscopy experiments therefore demonstrated a SERT-specific IDT318 
QD labeling for transiently transfected cultures which was not uniform across the entire 
cell population. This non-uniformity can be attributed to the transient transfection 
approach utilized to drive SERT expression, where only a fraction of the cells effectively 
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take up the plasmid and eventually express the encoded protein. This number of SERT 
positive cells in any given transfected cell population is therefore limited by transfection 
efficiency. However, the discriminate labeling of individual SERT positive cells within a 
mixed population does provide a further demonstration of SERT specificity.  
 
Flow Cytometry to Verify Specific SERT Labeling 
Fluorescent microscopy experiments were performed by simply depositing an aliquot 
of the cell suspension onto a glass slide and imaging once the cells had settled down to 
the focal plane. While this approach was effective at demonstrating specific labeling of 
SERT, the presence of cells outside the focal plane and large fluorescent aggregates 
frequently interfered with fluorescent imaging. The utilization of suspension cells, 
however, is perhaps more conducive to analysis by flow cytometry. Such an analysis 
provides the ability to rapidly assess the distribution of fluorescent intensities for an 
entire population of cells, and confers greater statistical certainty than photomicrographs 
of smaller numbers of cells. Flow cytometry analyses were subsequently performed on a 
BD LSRII flow cytometer available through the VMC Flow Cytometry Shared Resource.  
Population gates for all flow analyses were established from scatter parameters to ensure 
interrogation of only viable, single cells.  Histograms displaying the number of cells at a 
given QD fluorescence intensity, as illustrated in Figure 5-5, were generated using BD 
FACSDiVaTM software. SERT labeling is evident in these histograms as a shoulder at 
higher QD fluorescent intensity for SERT-expressing populations of cells (Figure 5-5, 
population indicated in orange). This population is diminished for both SERT-expressing 
cells pre-blocked with the SSRI paroxetine and sham-transfected cells lacking SERT, 
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indicating the specificity of IDT318 for SERT. Control experiments where SA-QDs were 
exposed to cells without IDT318 result in a dramatic decrease in fluorescence intensity 
across the entire population of cells (Figure 5-5, right). This finding indicates that the 
IDT318 ligand causes a uniform, nonspecific labeling due to ligand-mediated interactions 
with the cells, and the SERT specific labeling is only apparent at fluorescent intensities 
above this background. 
 
Figure 5-5. Flow cytometry analysis of different cell populations labeled with IDT318 targeted QDs. A 
population of cells specifically labeled for SERT is evident at higher fluorescent intensities for SERT 
expressing cells (left panel). This SERT-specific component can be blocked by pre-incubation with 
paroxetine and is not evident in sham-transfected populations (middle two panels). Control experiments 
using SA-QDs without the addition of IDT318 ligand indicates the presence of an added fluorescent 
background due to nonspecific, ligand-mediated cellular interactions. Fluorescent micrographs (inset) are in 
agreement with these findings. 
 
Optimized Parameters for Targeting SERT in Cellular Assays 
While the initial labeling conditions derived from successful labeling in Xenopus 
oocytes provided specific fluorescent imaging of SERT in a transiently transfected 
mammalian cell line, further modifications were required to optimize this SERT specific 
response of IDT318 in cellular assays.  Two parameters in particular, ligand incubation 
time and ligand concentration, proved to differ significantly from the oocyte model to a 
mammalian cell system. Optimization of these two critical parameters minimized the 
ligand-mediated fluorescent background and improved sensitivity in SERT detection. 
To assess the effect ligand incubation time has on specific SERT labeling, SERT-
transfected HEK-293T cells were exposed to a 1 μM of IDT318 in PBS for specific time 
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intervals between five minutes and one hour.  Sham-transfected HEK-293T cells were 
also exposed to identical conditions, and provided a suitable negative control for each 
time point.  The results of this time-course experiment, summarized in Figure 5-6, 
illustrate specific labeling of SERT after only five minutes of exposure to the ligand, 
while a maximal fluorescent response is attained within 10-20 minutes of ligand 
incubation. The ligand-mediated nonspecific background is also increased at longer 
incubation times, as indicated by the sham transfected populations shifting to higher 
fluorescent intensities, allowing for minimized nonspecific background with shorter 
incubation times. Minimizing, or altogether eliminating, this ligand-mediated background 
will act to increase the sensitivity of SERT detection and acts to enhance the detection 
specific SERT labeling. 
 
 
 
 
113 
Figure 5-6.  Determination of optimal incubation time for IDT318 labeling of SERT in cellular assays.  
Flow cytometry analysis of transiently transfected, SERT-expressing HEK-293T cells (SERT-293T, right 
column) demonstrate specific labeling of SERT at each time point as compared to sham-transfected cells 
lacking SERT (∅-293T, left column).  Quantification of the SERT positive population was determined for 
each time point, and is expressed as a percentage of the parent population above a 4% threshold, 
established from each time’s sham-transfected negative control.  Graphical representation of these data 
after background subtraction (right) indicate maximal SERT labeling after only 10-20 minutes of ligand 
exposure.  Longer incubation times cause an increase in the ligand-mediated background fluorescence 
which actually reduces detection of the SERT-positive population. 
 
Having identified 20 minutes as a suitable incubation time for IDT318 labeling of 
SERT, an investigation of the concentration dependence of IDT318 labeling was then 
conducted.  For this experiment, SERT-transfected HEK-293T cells were exposed to 
various concentrations of IDT318, each for 20 minutes.  As in the time-course analysis, 
sham-transfected cells were exposed to identical labeling conditions to provide a negative 
control at each concentration point.  The results, detailed in Figure 5-7, illustrate the 
concentration dependence for specific labeling of SERT with IDT318.  SERT specific 
labeling is evident at 100 nM IDT318 concentrations, and peaks around 500 nM.  At 
ligand concentrations above 1 μM however, the nonspecific ligand-mediated background 
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fluorescence once again overcomes the SERT-specific component, this time causing a 
dramatic decrease in SERT detection.  This nonspecific background shows a strong 
dependence on IDT318 concentration, and can be minimized with lower concentrations 
of IDT318 to provide more sensitivity for SERT detection. 
 
Figure 5-7.  Determination of optimal IDT318 concentration for labeling of SERT in cellular assays.  Flow 
cytometry analysis (left) as well as fluorescence imaging (inset) illustrates specific SERT labeling at 
specified concentrations.  Sham-transfected cells (left column) have an increased nonspecific background 
with increasing ligand concentration, while specific SERT labeling is evident in SERT expressing cells 
(right column) as a discrete population above this nonspecific background.  Quantification of the SERT 
positive population was determined for each concentration, and is expressed as a percentage of the parent 
population above a 4% threshold established from a sham-transfected negative control at each 
concentration.  Graphical representation of these data after background subtraction (right) indicate maximal 
SERT labeling at an IDT318 concentration of  500 nΜ.  Αt concentrations above 1 μM, however, the 
ligand-mediated background overtakes the SERT-specific signal, and compromises SERT detection. 
 
The Importance of Alkyl Chain Length in Ligand Design 
Previous competitive uptake assays with small molecule derivatives designed to 
target the dopamine transporter (DAT), an analogue of SERT which specifically 
transports the neurotransmitter dopamine, have indicated the importance of the alkyl 
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chain linker region which connects the bioactive drug derivative to the PEG backbone 
[153]. Consequently, analogues of IDT318 with varying alkyl chain lengths were utilized 
in cellular assays to assess the effect this linker arm length has on SERT labeling, and the 
results of this investigation are presented in Figure 5-8. A characteristic SERT-specific 
response is evident for IDT318 with roughly 28% of the cells exhibiting an increased 
fluorescent intensity due to specific labeling of SERT. This labeling is significantly 
diminished for the six-carbon IDT366 ligand, and altogether eliminated for the two-
carbon IDT317 ligand. Thus, the length of this alkyl chain has a dramatic effect on each 
individual ligand’s ability to specifically interact with SERT. This is likely due to the 
nature of the binding pocket for IDT318, with the added hydrophobicity somehow 
stabilizing IDT318’s interaction with SERT. Additionally, it is apparent that the ligand-
mediated nonspecific background increases with longer alkyl chain lengths, as indicated 
by a shift of the population to higher fluorescent intensities. Consequently, this ligand-
mediated background is likely the result of hydrophobic interactions with the cell surface, 
and subsequent ligand design should take into account the trade-off between specific 
labeling and nonspecific background depending on the length of the alkyl linker. 
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Figure 5-8. Alkyl chain length effect on SERT labeling in mammalian cell cultures.  It is apparent that 
minor modification to ligand structure can have a dramatic effect on SERT labeling.  Two carbon (IDT-
317, left column), six carbon (IDT-366, middle column) and eleven carbon (IDT-318, right column) alkyl 
spacers result in differential labeling of SERT.  Fluorescence images (inset) clearly demonstrate specific 
SERT labeling for the longer IDT-318, while this fluorescence intensity is diminished for both IDT-317 
and IDT-366.  Additionally, this increased SERT labeling is apparent in flow cytometry analyses, as 
indicated by an appreciable increase in fluorescent populations of SERT-expressing cells (top row) as 
compared to both paroxetine-blocked SERT cells (middle row) and sham transfected cells lacking SERT 
(bottom row). 
 
Specificity of IDT318 for SERT 
Fluorescent detection of SERT using IDT318-targeted QDs will eventually have to be 
performed in the presence of other monoamine transporters and cell surface receptors, 
especially considering one ultimate goal of multiplexed receptor detection in neuronal 
cultures. It was therefore crucial to further demonstrate SERT specificity even in the 
presence of similar transporter proteins. To assess the SERT-selectivity of IDT318, HEK-
293T cells were transiently transfected with plasmid cDNA encoding for DAT as a 
means of generating a cellular system with expression of an alternate monoamine 
117 
transporter. IDT318 labeling experiments were subsequently performed on both cell lines 
and the results are presented in Figure 5-9. IDT307, which is transported by both SERT 
and DAT, was initially utilized to verify successful transporter expression in both 
instances. The characteristic green intracellular fluorescence was observed for both SERT 
and DAT cultures (Figure 5-9, top row), indicating successful transfection of both 
plasmids. Fluorescent imaging (middle row) and flow cytometry analysis (bottom row) 
following IDT318 labeling demonstrated specific labeling of SERT with no apparent 
selectivity for DAT. This finding highlights the feasibility of utilizing small molecule QD 
targeting for multiplexed transporter detection in clinically relevant neuronal cultures. 
Further investigations are undoubtedly warranted to further demonstrate the selectivity of 
IDT318 for SERT over alternate serotonin cell surface receptors, which could 
additionally interfere with selective SERT detection in native tissues. 
 
 
Figure 5-9.  IDT-318 selectively labels SERT as compared to other monoamine transporters.  HEK-293T 
cells transiently transfected with SERT (left), DAT (middle) or empty pcDNA3.0 vector (right) were 
initially exposed to 5 μM IDT307 in order to assess transfection efficiency.  (A) IDT307 fluorescence is 
evident for SERT and DAT transfected cells, indicating successful transfection and expression of desired 
transporters, while no such fluorescence is apparent for sham-transfected cells.  Specific QD labeling of 
SERT with IDT-318 is evident in fluorescent micrographs (B) and flow cytometry analysis (C), while no 
significant labeling is observed for either DAT-transfected or sham-transfected cells, highlighting the 
specificity of IDT-318 for SERT over other monoamine transporters. 
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Summary and Future Direction 
 IDT318 has been successfully utilized to specifically interact with SERT and 
facilitate its fluorescent detection with SA-QDs. The QD labeling protocol was developed 
to circumvent several potential interferences, namely: (1) biotinylated ligands and a two-
step labeling were employed to eliminate the requirement of effectively presenting 
hydrophobic ligands at the QD surface, (2) serum proteins were eliminated from the 
protocol altogether to prevent protein adsorption to the QD surface, and (3) cells were 
labeled in suspension to reduce nonspecific QD interactions with the culture vessel. 
Ultimately, this labeling protocol provided negligible nonspecific binding due to QD 
interactions with cellular membranes, and SERT specific QD labeling was demonstrated 
using both fluorescence microscopy and flow cytometry. While IDT318 did cause an 
apparent nonspecific, ligand-mediated fluorescent background, the SERT-specific 
labeling was evident as an increased fluorescence above this background. Two critical 
parameters, ligand incubation time and concentration, were then investigated and a 
protocol incorporating a 20 minute incubation with 500 nM IDT318 provided the optimal 
fluorescent labeling conditions. The importance of the length of the alkyl chain 
connecting the bioactive drug derivative to the PEG backbone was also illustrated, and 
the eleven-carbon spacer of IDT318 is apparently required for SERT recognition. Finally, 
the selectivity of IDT318 for SERT was highlighted, with no apparent labeling of the 
alternate monoamine transporter DAT. 
A fluorescent assay which permits facile and rapid determination of SERT expression 
can be immediately useful for numerous biochemical applications. These fluorescent 
probes can be utilized to replace existing radiographic methodologies for assessments of 
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processes such as SERT expression, function, and localization. Such a fluorescent assay 
would provide improved spatial and temporal resolution without any of the drawbacks 
associated with isotopic substrate handling. Additionally, a fluorescent probe specific for 
SERT could be employed in dynamic imaging experiments to determine whether or not 
patterns of regulation and surface trafficking in transfected cells are applicable to 
neurons. Similar dynamic imaging studies can also be performed to verify the role 
integrins play upon its formation of a complex with SERT [154]. Ultimately, IDT318 
labeling of SERT expression in non-neuronal peripheral tissues, most notably in platelets, 
could eventually be utilized in the development of a routine diagnostic test to rapidly 
assess systemic levels of SERT expression or even identify mutational SERT variants. 
This screen could potentially aid in the diagnosis of disease states such as seasonal 
affective disorder or be utilized in determining a predisposed genetic susceptibility to 
diseases such as autism. A fluorescent assay to monitor SERT expression in platelets 
using IDT-318 targeted QDs could initially be developed to demonstrate differential 
SERT expression in platelets isolated from knockout (SERT-/-), heterozygous (SERT+/-) 
and wild type (SERT+/+) mouse models. Identification of differential levels of SERT 
expression in platelets isolated from individuals with specific disease states could 
ultimately be utilized to verify the predictive feasibility of this particular assay, and 
eventually result in the establishment of specific diagnostic criteria. 
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CHAPTER VI 
 
 
CONCLUSION 
 
 
This research has been focused on the integration of highly fluorescent quantum dots 
into biological assays in an attempt to utilize their unique spectral properties to better 
understand complex cellular processes. Initial efforts incorporated antibody-QD 
conjugates to monitor IL-2 expression in activated populations of Jurkat T cells [40]. 
Similar antibody targeting approaches have been employed to introduce specificity for a 
wide variety of biological QD applications, and antibodies have frequently been the first 
option considered for generating bioactive QDs. Numerous labeling protocols had been 
developed to minimize nonspecific interactions for antibody-QD conjugates, and these 
probes were not prone to any interferences due to serum blocking conditions. Antibody 
conjugates, however, were not without associated drawbacks, such as added steric bulk 
resulting in an increased probe size, variable strength antibody-antigen interactions, and 
excessive purchasing costs. Additionally, no suitable antibodies exist for 
immunofluorescent imaging of certain cellular targets, most notably SERT. Subsequent 
research efforts were therefore focused on the development of a small molecule targeting 
strategy to alleviate some of the problems frequently encountered with antibody-QD 
conjugates, and to generate QD probes capable of specifically interacting with SERT. 
Numerous technical challenges associated with the highly fluorescent AMP-QD 
platform had to be addressed prior to any successful demonstration of specific small 
molecule QD labeling. Preliminary investigations with AMP-QDs indicated that PEG 
modifications acted to reduce nonspecific cellular interactions [24], and subsequent 
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targeting ligands therefore utilized a PEG backbone to minimize any associated 
background fluorescence. It was then demonstrated for the first time that hydrophobic 
drug derivatives could self-assemble to the QD surface [149]. Attempts to utilize these 
conjugates in cellular assays ultimately failed to produce specific labeling, owing to the 
fact that the targeting functionality was associated with the QD surface and unable to 
interact with its intended target. Additionally, anomalous cellular imaging results led to 
the conclusion that proteins present in standard blocking solutions were adsorbing to the 
QD surface and causing artifact endosomal fluorescent staining. A better understanding 
of these unforeseen interferences ultimately permitted the development of a successful 
QD labeling protocol for SERT. Future investigators seeking to utilize small molecule 
QD conjugates for labeling membrane-associated receptors should undoubtedly be aware 
of these problematic interferences. 
One frequently encountered problem in attempting to demonstrate specific QD 
labeling was associated with the assumption that various cellular systems were in fact 
expressing the desired targets. Control experiments should be performed, whenever 
possible, to confirm expression of a target protein before assuming that the QD conjugate 
is ineffective. Numerous IL-2R labeling attempts failed initially due to the fact that 
cellular activation was not occurring as a result of degraded PMA. Similarly, cell lines 
stably transfected with SERT were utilized for numerous failed QD labeling attempts 
before determining that the cells had been passaged to a point where they no longer 
expressed SERT. IDT307 eventually provided a convenient means to assess transporter 
expression, eliminating a great deal of experimental uncertainty with regards to questions 
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of transporter expression. Subsequent investigations will benefit from the use of IDT307 
as a means of verifying successful transporter expression. 
A better understanding of potential interferences combined with the emergence of 
improved analytical tools (i.e. IDT307) ultimately culminated in the demonstration of QD 
labeling of SERT expressed in mammalian cell cultures. A transient transfection resulted 
in higher expression levels of SERT which was easily detectable by fluorescent 
microscopy and flow cytometry, and IDT307 was used to confirm successful transporter 
transfection prior to imaging experiments. Successful imaging of SERT in an oocyte 
model system with IDT318 eliminated any uncertainty regarding the effectiveness of this 
ligand, and optimal incubation conditions were found to differ significantly from an 
oocyte system to mammalian cell cultures. Imaging experiments performed with similar 
ligands eventually demonstrated the dramatic effect alkyl chain linker length plays in 
efficient SERT labeling. Additionally, the selectivity of IDT318 for SERT even in the 
presence of alternate monoamine transporters seems to indicate the possibility to 
interrogate SERT expression in native tissues, perhaps even in a multiplexed format to 
detect multiple cellular targets. 
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APPENDIX A 
 
 
FLUORESCENT IMAGING WITH IDT307: AN INTRACELLULARLY 
FLUORESCENT, MONOAMINE TRANSPORTER-SELECTIVE 
SMALL MOLECULE 
 
 
Fluorescent imaging experiments characterizing the cellular response of IDT307 were 
also performed throughout the course of this research, in addition to the previously 
described investigations utilizing quantum dots in biological applications. Traditionally, 
isotopic methods have been widely employed to measure biogenic amine transporter 
expression and inhibition. However, despite the added cost and associated hazards of 
radioactive isotope handling and disposal, these methodologies generally suffer from 
poor temporal and spatial resolutions limiting their utility in high throughput screening 
applications.  ASP+, or 4-(4-diethylaminostyryl)-N-methylpyridinium iodide, a 
fluorescent analogue of the neurotoxin MPP+, was initially identified as a suitable 
fluorescent substrate to facilitate a non-isotopic approach for the investigation of biogenic 
amine transporter localization, activity, and regulation [155, 156]. The search for 
improved fluorescent substrates based upon derivatives of ASP+ and MPP+ eventually 
resulted in the development of IDT307 (illustrated in Figure A-1), also referred to as 4-
(4-(dimethylamino)phenyl)-1-methylpyridinium iodide. A previous report has 
demonstrated the ability of this particular compound to form a host-guest complex with 
β-cyclodextrin, resulting in a fluorescent species with an emission maximum at 500-520 
nm due to the formation of a twisted intramolecular charge transfer (TICT) state upon 
excitation [157]. More recent cellular investigations with IDT307 have demonstrated its 
selective transport by the monoamine transporters for norepinephrine (NET), dopamine 
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(DAT), and serotonin (SERT), all resulting in a characteristic intracellular fluorescence 
[152]. 
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Figure A-1.  Structure of IDT307, an intracellularly fluorescent small molecule selectively transported by 
monoamine transporters. 
 
IDT307 has several intriguing characteristics which make it desirable for the 
development of a robust, non-isotopic platform to investigate monoamine transporters. 
Specifically, IDT307 is only fluorescent in specific environments, owing to the necessity 
of a TICT state for efficient fluorescence emission. Consequently, IDT307 has negligible 
fluorescence emission in aqueous environments without the addition of β-cyclodextrin, 
yet it is strongly fluorescent in specific intracellular environments. This unique 
fluorescent property permits IDT307 to be utilized without additional rinsing steps, as 
excess extracellular IDT307 does not result in an increased fluorescence background.  
Additionally, since IDT307 is specifically transported intracellularly by monoamine 
transporters, this characteristic intracellular fluorescence provides a useful signature to 
assess transporter expression and function. The intracellular fluorescent staining pattern 
observed upon addition of IDT307 to monoamine transporter expressing cell lines, 
illustrated Figure A-2 for hSERT-expressing HEK-293 cells, apparently results from 
interactions with distinct nuclear and cytosolic components. Finally, the intracellular 
accumulation of IDT307 can be blocked by traditional inhibitors of these monoamine 
transporters, highlighting the potential utility of this substrate for the development of a 
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high throughput drug discovery platform to identify clinically relevant transporter 
inhibitors. 
 
 
Figure A-2. Characteristic fluorescent staining pattern observed for monoamine transporter expressing cell 
lines upon exposure to IDT307. IDT307 is selectively delivered intracellularly by monoamine transporters, 
and its characteristic fluorescence consists of a nuclear component, a diffuse cytosolic component, with 
additional punctate cytosolic labeling. 
 
Having demonstrated the specificity of this fluorescent substrate for the monoamine 
transporters SERT, DAT and NET, initial characterization efforts were focused both on 
determining the intracellular fate of IDT307 following transport as well as characterizing 
its fluorescent emission. Obtaining a fluorescent emission spectrum of IDT307, however, 
provided a unique technical challenge given that a TICT excited state is required for 
fluorescent emission. Fluorescent spectra were initially acquired in solution following the 
addition of β-cyclodextrin, but improved fluorescent detection would characterize the 
spectral properties of IDT307 in vitro. Consequently, LLC-PK1 cells stably transfected to 
express rDAT (dopamine transporter derived from rats) were incubated with a 10 μM 
IDT307 solution in KRH buffer for 30 minutes. Following one rinse with cold KRH, the 
cells were imaged on a Zeiss LSM 510 inverted confocal microscope using a specialized 
Meta detector.  This Meta detector is capable of acquiring as many as 32 individual 
fluorescent images at distinct wavelength intervals (Figure A-3, left), ultimately allowing 
the determination of spectral information. ImageJ image analysis software was 
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subsequently used to determine the integrated intensity for each image and generate 
relevant emission spectra (Figure A-3, right). The fluorescent emission maxima in cell 
cultures occurs at ~510 nm, while the observed emission maxima for β-cyclodextrin-
IDT307 host-guest complexes is at 485 nm. This shift in emission maxima is likely due to 
the solvochromatic nature of these TICT compounds. 
 
Figure A-3. Spectral analysis of IDT307 intracellular fluorescence. Spectral analysis could not be 
performed in solution due to the necessity of a TICT excited state for fluorescent emission. Therefore 
spectral analysis was performed using the Zeiss LSM 510 Meta detector which acquires a series of 
fluorescent images at 10 nm increments (left). These images can then be displayed as an emission spectrum 
by measuring the integrated fluorescent intensity for each image (ImageJ Software) and plotting it as a 
function of wavelength (right). 
 
Fluorescent imaging analysis was also performed to characterize the intracellular fate 
of IDT307. The unique intracellular fluorescence of IDT307 consists of a nuclear 
component, a diffuse cytosolic component, with additional punctate cytosolic labeling 
(Figure A-1). Colocalization studies were therefore performed in an effort to determine 
specific cellular components corresponding to the fluorescence of IDT307. Specifically, 
the membrane-permient fluorescent dyes STYO-17, BODIPY-TR, MitoTracker Red, and 
LysoTracker Red (all from Invitrogen Corp.) were utilized to fluorescently stain for 
nucleic acids, the Golgi apparatus, mitochondria and lysosomes, respectively. Red 
fluorescent cellular dyes were specifically chosen to eliminate any potential spectral 
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overlap with the green fluorescence of IDT307. As such, HEK-293 cells stably 
transfected with hNET were initially exposed to a solution containing both the specified 
red-fluorescent cellular component dye and IDT307 (10 μM) for 30 minutes in KRH 
buffer. The labeling solution was then removed by aspiration, and the cells were 
subsequently rinsed once with cold KRH buffer. These fluorescently labeled cells were 
then imaged immediately on a Zeiss LSM 510 Meta confocal microscope, and 
representative dual color and colocalization images are displayed in Figure A-4. Dual 
color fluorescent images were acquired with appropriate band-pass (green channel) and 
long-pass (red channel) filter settings for optimized fluorescence detection, and dual 
excitation sources (488 nm excitation for green channel, and 543/633 nm excitation for 
red channel) were used to eliminate bleed-through from the green channel into the red 
channel. 
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Figure A-4. Determining the intracellular localization of IDT307 using various fluorescent cellular 
organelle indicators. All images acquired on a Zeiss LSM-510 META confocal microscope using a 100× 
oil-immersion objective. A high degree of colocalization with a nucleic acid indicator (top left) is indicative 
of IDT307 localization to the nucleoli as well as the observed diffuse cytosolic staining. No appreciable 
accumulation at the Golgi apparatus as indicated by a BODIPY fluorescent indicator (top right).  
Additional punctant cytosolic labeling, not resulting from nucleic acid interactions, appears to be due to 
either mitochondrial association (bottom left) or lysosomal association (bottom right). 
 
As anticipated, the intracellular fluorescence of IDT307 clearly colocalizes to a great 
extent with the nucleic acid stain SYTO-17 (Figure A-4, upper left).  Therefore, both the 
diffuse cytosolic labeling and the nucleoli labeling of intracellular IDT307 can therefore 
be attributed to nucleic acid interactions. While IDT307 does not appear to colocalize 
with the Golgi apparatus (A-4, upper right), it is not immediately apparent whether the 
punctate cytosolic labeling component results from interactions with intracellular 
mitochondria (A-4, lower left) or lysosomes (A-4, lower right). It is likely that this 
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fluorescence is the result of interactions of IDT307 with mitochondrial DNA, having 
already demonstrated that nucleic acid interactions have an apparent effect on the 
fluorescence of IDT307. Indeed, closer examination of hNET expressing HEK-293 cells 
labeled with both MitoTracker Red and IDT307 clearly indicate an apparent 
mitochondrial colocalization (Figure A-5). 
 
 
Figure A-5. Demonstrating colocalization of IDT307 intracellular fluorescence with mitochondria. 
Additional fluorescent imaging with MitoTracker Red provides convincing evidence that the punctate 
cytosolic fluorescent labeling observed for IDT307 is associated with mitochondria. (Note: the brightfield 
image has been eliminated to provide a clearer demonstration of colocalization.) 
 
This appendix has described the microscopic approaches utilized to characterize the 
intracellular properties of IDT307, while a more detailed discussion of the unique cellular 
and fluorescent properties of this compound is currently in preparation [152]. The Zeiss 
LSM 510 Meta has proven to be a useful tool in determining the spectral properties of the 
fluorescent emission of IDT307 in vitro. The observed fluorescence emission spectrum of 
IDT307, with maximal emission at ~510 nm, permits its routine detection on standard 
fluorescence microscopes using any traditional GFP filter set. Additionally, the unique 
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fluorescent properties of IDT307 permit monoamine transporter analysis without required 
washes, owing to the fact that extracellular IDT307 does not significantly contribute to a 
fluorescence background signal.  Routine analysis can therefore be performed simply by 
adding 1-10 μM IDT307 directly to the cell culture media, and subsequently imaging on 
a fluorescent microscope (equipped with a GFP filter set) after just 5-10 min incubation 
at 37 °C. As such, analyses utilizing IDT307 have proven to be extremely useful as a 
means of verifying monoamine transporter expression. Furthermore, dual color 
fluorescent imaging experiments have confirmed that the observed intracellular 
fluorescence for IDT307 is due to interactions with nucleic acids.  The characteristic 
fluorescent staining pattern observed for IDT307 cells consists of both distinct labeling of 
the nucleoli and a diffuse cytosolic labeling as a result of these nucleic acid interactions, 
with an additional punctate cytosolic labeling due to an interaction with mitochondrial 
DNA. 
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